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BACKGROUND 
Epilepsy is a neurological disorder characterized by abnormal changes 
in the brain’s electrical potentials. Brainstem Auditory Evoked Potential 
(BAEP) is an important clinical tool in studying the electrophysiological 
phenomena of neural excitation, conduction and transmission across the 
auditory pathway. It has been widely used for the early detection of neural 
conduction irregularities in auditory pathway. Using BAEP, we can easily 
detect the early changes occurring in the auditory pathway in Generalized 
Tonic Clonic Seizure(GTCS) patients even before the clinical manifestation 
of hearing impairment occurs so that proper measures to intervene the disease 
process at the earliest possible is achieved to provide a better quality of life 
for GTCS patients. 
AIM OF THE STUDY 
· To determine the functional integrity of auditory pathway in 
patients with GTCS by recording brainstem auditory evoked 
potential. 
· To assess serum Interleukin -1 beta levels in these patients. 
· To find the correlation between serum Interleukin-1 beta level and 
Brainstem auditory evoked potential in patients with GTCS. 
MATERIALS AND METHODS 
 30 patients with GTCS of both sexes in the age group 20-40 years 
without any clinical evidence of hearing impairment were included in the 
study. Controls were age, sex and BMI matched healthy population. Both the 
controls  and  GTCS  patients  were  subjected  to  BAEP  and  serum  
interleukin-1beta levels were also measured. The data were analyzed by 
Student ‘t’ test. 
RESULT 
GTCS patients showed significant differences in wave III, V absolute 
latency  and  I-III,  I-V  IPL  of  BAEP.  The  interleukin-1β levels  were  
significantly prolonged in GTCS patients as compared to control population 
suggesting the contribution of this cytokine in epileptogenesis. 
  
CONCLUSION 
There was significant prolongation of central conduction time in 
GTCS patients even though there was no clinical evidence of hearing 
impairment assessed by pure tone audiogram prior to the study. Hence BAEP 
can be utilized as an objective electrophysiological tool to evaluate the 
functional integrity of auditory pathway from the external ear to lower 
brainstem. 
KEY WORDS 
Generalized tonic clonic seizures, Brainstem auditory evoked 
potential, Absolute latency, Interpeak latency.  
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1. INTRODUCTION 
A seizure (derived from Latin word Sacire meaning to take possession 
of)  is  a  paroxysmal  event  which  occurs  due  to  abnormal  excessive  or  
synchronous neuronal activity in a discrete or generalized portion of brain. 
Seizures can be provoked by acute brain insult or systemic diseases 
like stroke or metabolic causes but if it occurs in the absence of an acute 
provoked event, it is termed as unprovoked seizure1. Epilepsy is defined as 
the tendency to have at least two episodes of unprovoked seizures separated 
by a minimum period of 24 hours. 
In 2005, International League Against Epilepsy (ILAE) and 
International Bureau of Epilepsy (IBE) proposed the definition of epilepsy as 
a disorder of brain by an enduring predisposition to generate epileptic 
seizures and by the neurobiological, cognitive, psychological and social 
consequences of this condition. 
Efforts to classify epileptic seizures date back to the earliest of  
medical literature. In 1964, the Commission on classification and 
terminology of ILAE proposed the first official classification of epileptic 
seizures which was revised in 19812,3. 
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ILAE classification of epileptic seizures 
I. Partial (focal, local) seizures 
A. Simple partial seizures (consciousness not impaired) 
-with motor symptoms 
-with somatosensory or special sensory symptoms 
-with autonomic symptoms 
-with psychic symptoms 
B. Complex partial seizures (with impairment of consciousness) 
-with simple partial onset followed by impairment of consciousness 
-with impairment of consciousness at onset 
C. Partial seizures evolving to secondarily generalized seizures 
-SPS evolving to generalized seizures 
-CPS evolving to generalized seizures 
-SPS evolving to CPS evolving to generalized seizures 
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II. Generalized seizures (convulsive or non -convulsive) 
-Absence seizures 
1. Typical absence seizures 
2. Atypical absence seizures 
-Myoclonic seizures 
-Clonic seizures 
-Tonic seizures 
-Tonic clonic seizures 
-Atonic seizures 
III. Unclassified epileptic seizures 
           The ILAE described generalized seizures as “In seizures that are 
generalized at onset, the abnormal activity probably originates in the central 
mechanisms controlling cortical activation and then it spreads rapidly”. So 
generalized seizures are rightly defined as originating at some point within 
and rapidly engaging, bilaterally distributed networks which does not 
necessarily include the entire cortex. They begin with simultaneous and 
almost equal involvement of both cerebral hemispheres from the onset and 
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involve the deeper thalamic, subcortical and brainstem structures in a 
feedback loop to the cortices. 
FIGURE 1: Cross section of brain showing primary generalized seizure 
 
 
 
 
Generalized tonic clonic seizures are the most commonly encountered 
seizures in both children and adults, the classic picture which the public 
generically perceives as epilepsy. The glossary of descriptive terminology for 
ictal semiology provided by ILAE taskforce describes a tonic clonic seizure 
as “a sequence consisting of a tonic followed by a clonic phase .Variants such 
as clonic-tonic –clonic may be seen”102. 
A  GTCS  may  be  of  generalized  onset  (primarily  GTCS)  or  it  may  
begin focally, followed by secondary generalization (secondarily 
generalized). The clinical manifestations observed in these seizures are 
initiated by abnormal electrical discharges within the brain and depend on the 
part of brain involved in epileptic neuronal discharge and the intensity of 
discharge. They are sudden, transient and usually brief which include motor, 
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psychic, autonomic and sensory phenomena with or without alteration in 
consciousness and awareness. 
Brainstem auditory evoked potentials are electrophysiological 
recordings of responses from within the auditory system that are activated by 
sounds. They are recorded from the ear and vertex in response to a brief 
auditory stimulation to assess the conduction through auditory pathways up 
to midbrain. The human Brainstem auditory evoked potentials (BAEP) 
consist of far field evoked potentials from the auditory nervous system. The 
BAEP is the averaged surface recorded activity from multiple source neural 
generators in the peripheral and lower central auditory nervous system and 
represents the synchronous discharge activity of onset –sensitive single units 
from first through sixth order neurons. The evoked transient responses can be 
recorded up to 500 ms from time of onset of the sound stimulus. The evoked 
potentials of the first 10 ms i.e.) short latency response (SLR) is popularly 
known as Brainstem auditory evoked potentials  (BAEP).  
BAEP comprises of 5 or more waves within 10 ms of stimulus and 3 
interpeak latencies. Each individual wave and interpeak latencies provide 
information about an area of auditory pathway starting with cochlear nerve to 
the level of inferior colliculi. These were first described by Jewett and 
Williston in 1971. 
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Epilepsy is a neurological disorder characterized by abnormal changes 
in the brain’s electrical potentials. The dysfunction occurring at the cellular 
level leads to excessive neuronal excitability and AEPs are expected to be 
altered  by  such  cellular  dysfunction.  Hence  BAEPs  have  emerged  as  an  
important clinical tool in studying the electrophysiological phenomena of 
neural excitation, conduction and transmission across the auditory pathway 
(Tandon OP et al 1990)4. 
Cytokines are soluble potent glycoproteins secreted by the glial cells of 
CNS and they function as immune system mediators. They mediate cell to 
cell sigalling by binding to high affinity surface receptors and serve as a 
biomarker for earlier detection of brain damage to prevent further 
neurological complications. Abnormalities in the expression of cytokines and 
immune cells is noted in epilepsy patients and in various animal models (Jobe 
PC et al 1991)5 and hence the immune system and its associated 
inflammatory reactions appear to play a major role in epileptogenesis and 
aggravate brain damage (Holmes et al 2002)6. Epilepsy per se is capable of 
producing elevated levels of cytokines. Such elevated levels as during 
inflammation of brain or periphery decreases seizure threshold and 
predisposes to epilepsy.  
Interleukin-1beta (IL-1β) is one such pro inflammatory cytokine 
released from glial cells during seizures. Many CNS diseases such as seizure 
and cerebral ischemia are associated with BBB leakage which leads to 
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extravasation of CNS-foreign proteins like albumin and simultaneously the 
excitotoxic damage produced by such diseases causes increased microglial 
IL-1β expression. This leads to reduced seizure threshold and epilepsy which 
depends on the amount of neuronal IL-1RI and IL-1RII.   
     The chronic expression of IL-1β during epileptogenesis 
contributing to neuronal injury suggests that IL-1 β activated pathways play a 
vital role in the genesis of spontaneous seizures, thus raising the possibility of 
using IL-1 antagonist as a novel drug for seizure inhibition in clinical practice 
(Randle et al 2001)103. IL-1 production and activity are regulated by many 
factors like caspase-1, IL-1RI, IL-1RII, IL-Ira which implies there are many 
ways to interfere with IL-1β activity, of which the anticonvulsive effects can 
be explored. IL-1β also influence many central neurotransmitters including 
GABA, 5-hydroxy tryptamine, noradrenaline and acetyl choline as well as 
expression of a number of neuropeptides in several brain regions contributing 
to changes in auditory evoked potentials of GTCS patients. 
Hence considering the above factors, the present study is undertaken to 
assess the functional integrity of auditory pathway using Brainstem evoked 
response audiometry in patients with generalized tonic clonic  seizures. We 
also compare serum Interleukin-1β levels in patients with GTCS and normal 
controls and then correlate their levels with BAEPs in GTCS patients. 
 
2. REVIEW OF 
LITERATURE   
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2. REVIEW OF LITERATURE 
Seizure is one of the most dramatic example of the collective electrical 
behaviour of the mammalian brain It is generally a chronic problem with 
significant impact on personal, social and economic aspects, often affecting 
the ability to hold jobs and drive. Generalised tonic clonic seizures are the 
best recognised form of seizures often presenting with loss of consciousness 
and a generalised tonic contraction evolving gradually into clonic activity. 
BAEP is an objective neurophysiological test used to evaluate the 
neural activity from the external ear to lower brainstem. This non-invasive 
tool can be utilized in GTCS patients for early detection of neural conduction 
irregularities in the auditory pathway. A few studies in this field of research 
have shown an increase in the latency of   BAEP waves and so with this 
background , the present study has been taken up to assess the integrity of 
auditory pathway  in GTCS patients by recording brainstem auditory evoked 
potentials. 
As several researches have high-lighted the intrinsic role of 
interleukin-1β in the process of epileptogenesis, the present study is aimed at 
measuring serum Interlukin-1β levels in GTCS patients so that the 
antagonists of this cytokine can be used in clinical practice for seizure 
inhibition in near future.  
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Epilepsy had been one of the earliest and commonly recognised 
neurological disorders (Temkin O et al 1994)7. The earliest references to the 
disorder dates back to second millennium BC where Mesopotamian writings 
described it as antasabbu literally meaning the falling disease. Indian 
Ayurvedic writings roughly belonging to the same period also contain 
elaborate clinical description of epilepsy as ashepak or apasmara. In 400 BC, 
epilepsy was called sacred disease because people believed that people 
suffering from seizures were possessed by evil spirits or gods and should be 
treated by the invocation of religious, occult and magical powers. 
Hippocrates, the Father of Medicine made the notable conceptual 
contribution saying epilepsy is an illness as any other disease and no more 
considered divine or spiritual. He proposed that brain is the organ where the 
site of  seizure onset is located and also revealed the existence of genetic 
basis in epileptic patients.  
Galen, a Greek physician introduced the term aura to describe the 
symptoms that preceded the onset of epilepsy.  
Tissot recognised two types of ictal events, GTCS which he called 
grands acces and absence seizures as petits acces. 
In 1873, David Ferrier the Scottish neurologist clearly demonstrated in 
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monkeys that motor cortex and not medulla initiated the convulsive motor 
activity.  
John Hughlings Jackson (1835-1911), the father of epilepsy confirmed 
the relationship that existed between the structure and physiology of the 
nervous system to elucidate the pathophysiology associated with seizures. He 
also supported the findings of David Ferrier regarding the site of seizure onset 
and implicated that the ictal behaviour correlated well with the region of 
functional anatomy. The potential therapeutic importance of his intellectual 
conclusion was that the surgical treatment may be effective as an underlying 
pathology or structural lesion was presumed to be associated with the site of 
epileptogenesis. 
Victor Horseley performed the first surgery for epilepsy in 1886 by 
resecting a traumatic cortical scar in a patient with focal motor seizure 
rendering him seizure free.  
Hans Berger’s invention of electroencephalogram in 1929 made a 
historical revolutionary impact on the diagnosis of epilepsy. 
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2.1.1. Epidemiology 
The incidence of epilepsy is 0.3-0.5% in the world population which is 
age dependent. Along with various studies, Hirtz D et al also have shown that 
higher rates occur in infants younger than one year and a second peak is found 
in people older than 60 years presenting with bimodal distribution8. Seizures 
are  so  common  to  occur  in  10%of  the  population  at  some  point  in  their  
lifetime (Berg et al 1991)9. Sex specific incidence rates are not usually 
significant, although the incidence rates are almost always higher for males as 
compared to females. The prevalence is estimated to be 5-10 persons /1000 
which is higher in developing countries. Sridharan et al estimated the 
prevalence in Indian population to be 1% which is higher in rural than urban 
population 10. 
Perhaps more important than incidence and prevalence in 
understanding the impact  of  epilepsy as a worldwide health problem is  the 
global burden of the disease which is measured by Disability Adjusted Life 
Years(DALYs) and number of life years lost due to disability or death(YLL). 
According to WHO, epilepsy was estimated to account 0.5% of the global 
burden of disease with 7.3 million DALYs and 1.32 million YLL11. 
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2.1.2 Etiology 
1. In 60-70% of patients with seizures, no specific cause is identified 
which is commonly referred as idiopathic. 
2. Genetic- risk is increased 2-3 times in individuals having first degree 
relatives with epilepsy. 
3. Infants and children- congenital malformations, perinatal injuries or 
hypoxia, developmental neurological disorders, metabolic defects, 
injuries and infections.  
4. Young adults- head trauma, brain tumours, infections and arteriovenous 
malformations. 
5. Elderly – cerebrovascular disease, CNS degenerative diseases, brain 
tumours. 
6. Drugs- antihistamines, narcotic analgesics and iodinated contrast agents 
like metrizamide (Messing RO et al 1984) 12. 
2.1.3. Genetics and Epilepsy13 
Most of the seizures are believed to be complex traits resulting from 
interactions between non genetic and genetic factors, the latter thought to 
provide minor contributions from multiple genes (oligogenic or polygenic) 
and thus the patterns of inheritance in majority of seizures are complex and 
subtle. 
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      Many generalised seizures in humans have revealed a genetic basis and 
these almost become apparent before the age of 35 years. Recent studies 
suggest that the mutations affecting the ion channel function and 
chromosomal microdeletion may be the cause of epilepsy in a subset of 
patients.  
      Tan  NC et  al14 have quoted many association studies that have been 
undertaken to examine the influence of common genetic variation on disease 
susceptibility in epilepsy, but unfortunately no genetic variants have been 
proven to underlie any common epilepsy. Studies in twins have demonstrated 
concordance rates as high as 70% in monozygotic and 10% in dizygotic pairs 
implying that factors other than genetics play a role in the occurrence of 
seizures (Treiman et al 1993)15.   
Triggering factors for seizures include 
-Sleep deprivation 
-Physical and mental exhaustion 
-Flickering lights including television and computer screens 
-Alcohol (particularly withdrawal) 
-Intercurrent infections or metabolic disturbances 
-Missed doses of antiepileptic drugs in patients undergoing treatment 
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2.1.4. Comorbidities in Epilepsy 
Individuals with epilepsy are at risk for increased morbidity and 
mortality  as  compared  to  general  population.  Patients  with  drug  resistant  
epilepsy and longer duration of the disorder contribute significantly to higher 
morbidity in various surveys due to the result of stress and its adverse effects 
on various systems. In patients with newly diagnosed epilepsy, 18% of them 
present with additional dementia, 6% motor disabilities and 6% with severe 
psychiatric disturbances. So about 1 in 15 of patients with seizures depend on 
others for daily living due to associated handicaps. Poor epilepsy control and 
seizure themselves can lead to significant cognitive and personality changes 
as well as chronic depression. It results in social stigmatisation resulting in 
isolation which further creates problem in education, employment, personal 
relationships and family life. 
Patients  with  epilepsy  have  2-3  times  greater  risk  of  mortality  than  
expected in a matched population without epilepsy. SUDEP accounts for 
about 1.7% deaths in epilepsy which when witnessed is most often associated 
with GTCS near the time of death. 
2.1.5. Pathophysiology of Seizures 
The electro physiologic and molecular mechanisms that underlie the 
pathophysiology of seizures is poorly understood. Animal models using 
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maximal electroshock or chemoconvulsants such as pentylenetetrazol have 
been utilised to probe into the pathophysiology of focal and generalised 
seizures. 
   Seizures are linked at the lowest level to membrane potentials, ionic 
fluxes  and  generation  of  action  potentials.  The  RMP  of  the  neuronal  
membrane is approximately about -70mV. In neurons the action potential is 
generated due to changes in the permeability of sodium, chloride, calcium 
and potassium ions which enter and exit the neurons by voltage dependent 
channels. At threshold voltage there is Na+ influx due to high permeability of 
these ions, the membrane potential becomes dramatically positive (+60 mV) 
which generates the action potential. After 1ms Na+ channels are inactivated 
followed by K+ efflux  and  the  coincident  Cl-- influx result in membrane 
hyperpolarisation and the termination of electrical activity at that point along 
the cell membrane (Hille B et al 1984)16. 
   As the action potential reaches the axon terminal, voltage dependent 
Calcium channels open, permitting Calcium influx into presynaptic terminals 
which results in neurotransmitter release. Hence any changes or 
abnormalities at any point along this electric cascade will have a significant 
impact on the excitability and epileptogenecity of the individual neuron (Mc 
Namara JO et al 1994) 17. 
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   The effects of neuronal activity are mediated through synaptic 
connections existing between neocortical, thalamocortical and 
corticothalamic projections. The impulses finally culminate in either 
excitatory (EPSP) or inhibitory postsynaptic potentials (IPSP). Excitatory 
inputs are transmitted by neurotransmitters like glutamate and aspartate 
whereas inhibitory inputs are mediated by gamma aminobutyric acid 
(GABA). 
   Seizure propagation is likely to occur in cells with intrinsic bursting 
if the balance between excitatory and inhibitory inputs is altered. Neurons 
begin to fire synchronously leading to a seizure in the absence of appropriate 
inhibitory regulation (loss of IPSPs).  
   Goldensohn et al18 proposed a hypothesis that the neurons within 
the epileptic focus of cortex undergo paroxysmal synchronous depolarisation 
termed as paroxysmal depolarizing shift(PDS) resulting in an abnormal burst 
of action potentials which continue in synchronous volleys without 
appropriate inhibition. 
2.1.6. Neurotransmitters 
GABA is found to be a critical inhibitory modulator of neuronal 
activity  in  the  brain  (Gale  K  et  al  1992)19. It generates IPSPs mediating 
synaptic inhibition which counterbalances the excitatory inputs from other 
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regions of brain. Three distinct types of GABA receptors are identified. 
GABA-A,  B,  C.  GABA-A  receptor,  a  pentameric  complex  is  organised  to  
form a chloride channel through which Cl- ions  can  enter  into  the  
postsynaptic  region.  When  GABA  binds  with  GABA-A  receptor,  there  is  
influx of Cl- ions resulting in generation of IPSP. Wallace et al20 found that 
mutations of GABRG2 gene encoding for GABA-A subunit leads to 
generalised and febrile seizures. 
Lothman E et al21 suggest that disruption of GABAergic function may 
be central to the molecular pathophysiology of seizures. Hence interruption 
of integrated GABA mediated inhibition in cortex will result in a lowered 
threshold for ictal discharges. Various animal models have supported this 
mechanism which shows that GABA agonists prevent seizures while 
antagonists may provoke seizures. 
FIGURE 2: GABA in epileptogenesis 
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Glutamate and aspartate are excitatory neurotransmitters which act by 
binding to EAA receptors resulting in enhanced intracellular Calcium levels. 
This causes activation of proteases and lipases and osmotic swelling of 
neurons resulting in cell death.  
Meldrum B et al proved in his study that glutamate and aspartate 
contribute to the initiation, spread and maintenance of epileptic activity in 
cortex22. 
During MJ et al studied in epilepsy patients to confirm increased levels 
of EAA compounds such as aspartate using micro dialysis catheters 
immediately prior to the onset of seizure activity23. 
2.1.7. Effects of Seizures on Brain 
Ischemia /infarction, trauma and seizure are three major forms of acute 
brain injury which leads to significant neuronal loss resulting in neuronal 
dysfunction. There may be some common cellular mechanisms involved in 
these pathologies, but the induction of cell death following seizure activity is 
probably less well understood than other forms of brain injury (Liou AK et al 
2003)24.   
Delorenzo RJ et al observed that following a prolonged seizure, there is 
excessive release of excitatory neurotransmitter, which activates N methyl D 
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aspartate(NMDA) receptors and voltage activated Calcium channels that 
results in cellular influx of Calcium ions25. An increase in free calcium tends 
to produce mitochondrial dysfunction with activation of various enzymes like 
lipases, endonucleases, proteases etc. In addition, free radicals are generated 
contributing to mitochondrial dysfunction26 and ultrastructural changes may 
be observed after 30-60 min of seizures (Meldrum BS et al 2002)27. This 
results in reversible or irreversible neuronal damage and CSF markers of 
neuronal injury like neuron specific enolase increase following seizure 
activity (Pitkanen S et al 2002)28. 
  Prolonged seizures may ultimately result in neuronal death by either 
necrotic or apoptotic pathways. Based on classic morphological definitions, 
cell necrosis appear to be the dominant mechanism, the exception being 
granule cell death in the dentate gyrus including recently generated neurons 
in this region which more readily show apoptosis (Ekdhal CT et al 2003)29. 
However animal models suggested varying ratios of apoptic vs necrotic cell 
death suggesting heterogeneity in the cellular effects of seizures. This state of 
flux  is  found  to  be  dependent  on  energy  state  of  the  cell  and  on  the  time  
course and severity of the neurotoxic insult, cell necrosis being observed with 
severe excitototoxic insults and apoptosis with milder insults to more resilient 
neurons which allows the induction of more delayed energy dependent cell 
pathways (Kondratyev A et al 2004)30. 
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  Thus epileptic seizures can cause severe and long lasting events on 
the brain architecture including neuronal cell death, accompanied 
neurogenesis, reactive gliosis and mossy fibre sprouting. 
2.1.8. Generalised Tonic Clonic Seizures 
Gestaut and Broughton gave an elaborate description of the semiology 
and pathophysiology of GTCS32. By stressing the stereotypical nature of 
GTCS, they divided it into 4 distinct phases 
1. Preictal manifestations 
2.Ictal manifestations (with loss of consciousness) 
   a. Tonic phase (includes intermediate vibratory phase) 
         b.  Clonic  phase  
         c. (concurrent) Autonomic changes 
3. Immediate postictal features 
4. Late postictal features 
      According to Gestaut and Broughton, preictal manifestations are brief 
with bilateral myoclonic contractions which immediately precedes the onset 
of tonic phase. But Fisch BJ et al33 defines it as prodromal phase presenting 
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with nonspecific symptoms such as headache, irritability, lethargy, mood 
changes and sleep disturbances. These symptoms actually do not represent 
epileptic aura but reflect the physiological changes that reduce the seizure 
threshold. If aura occurs before a seizure, it indicates that the tonic clonic 
seizure is secondarily generalised. 
GTCS synonymous with the previous term grandmal epilepsy or 
convulsions is the classical and best recognised form of seizures which 
typifies epilepsy in public imagination. These seizures do not have an aura 
but preceded by a prodrome that occurs for minutes to a few hours before a 
seizure which includes inconsistent nonspecific premonitory symptoms like 
ill-defined anxiety, instability, reduced concentration, headache or vague 
uncomfortable feelings.  
The seizure onset is abrupt often presenting with loss of consciousness 
followed  by  the  tonic  phase.  In  this  phase  the  patient  tends  to  fall  if  he  is  
standing with bilateral tonic extension of trunk and extremities followed by 
synchronous muscle jerks. This phase can have asymmetrical movement 
which often varies from seizure to seizure and one such commonly observed 
asymmetry is versive head turning which is not an evidence of focal onset. It 
also includes upward deviation with partially opened eyes and mouth is also 
opened. 
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      Involvement of respiratory muscles produces epileptic cry which is 
characterised by forced expiration that produces a loud guttural localisation. 
Cyanosis may occur in this phase in association with apnoea. Autonomic 
signs are present during this phase which includes tachycardia, hypertension, 
cyanosis, salivation, sweating and incontinence of urine or stools.  
      Benarroch EE et al was able to elucidate that increase in heart rate and 
blood pressure was either mediated directly through the ictal activation of 
structures of the central autonomic network which includes  insular cortex, 
amygdala, hypothalamus, periaqueductal grey matter, para brachial complex, 
NTS and ventrolateral medulla or reflecting the high metabolic demand of the 
seizure. 
Plum F et al34 reported that the rise in blood pressure evoked by seizure 
usually causes a significant increase in cerebral blood flow to meet the 
increased metabolic demands of brain. 
      Bateman LM etal observed that when diaphragm and 
thoracoabdominal muscles are involved during the tonic phase, it results in 
insufficient air exchange, which in turn may lead to alveolar hypoventilation 
causing decrease in blood O2 saturation and cyanosis. 
      This stage lasts on an average of 10-30 sec and gradually evolves into 
clonic activity. The transition can be initially of high frequency and low 
amplitude motion often referred as the vibratory phase. 
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      As the cortical discharges diminish with frequency, the clonic phase 
ensues where the limbs produce repetitive myoclonic jerks for a variable 
time. With seizure progression, the frequency of clonic jerks reduces and the 
amplitude which rises initially also decreases just before the seizure stops.   
The final phase lasts for 2-30 min and is characterised by flaccidity of 
muscles and diminished tendon jerks. 
      Confusion and unresponsiveness is invariable in the postictal period. 
Respiration is loud and stertorous in nature. In this phase the patient feels 
dazed with a severe headache and extremely unwell, he often lapses into a 
deep sleep. On awakening within minutes or hours later, some residual 
symptoms may persist which include headache, dysthymia, lethargy and 
generalised muscle soreness. GTCS rarely last greater than 2 minutes and the 
postictal  state  is  found  to  be  correlated  with  severity  and  duration  of  the  
seizure episode.  
2.1.9. Diagnosis of Epilepsy 
          In assessment of a patient with epilepsy, the history takes primacy 
ideally in conjunction with an eye witness account. In a vast majority of cases 
the diagnosis of epilepsy is clinical but a syndromic diagnosis is also possible 
on the basis of clinical signs and symptoms. 
         EEG optimally undertaken with video recording assists in 
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confirming the diagnosis and type of epilepsy (focal vs generalised) and also 
in localising the area of seizure onset. EEG must be performed, it is more 
likely to be abnormal within first 2 days after a seizure31. Ictal EEG findings 
at onset include high amplitude anteriorly dominant generalised spike wave 
discharges, diffuse fast frequencies that evolve to generalised spike wave 
discharges or polyspike wave discharges. 
     Once the seizure is clinically manifest, the muscle activity prevents the 
determination  of  EEG  changes.  Post  ictally  the  EEG  often  shows  diffuse  
slowing ie) slow spike wave discharges. Inter ictal EEG shows either a 
normal background or runs of occipital delta activity and may show either 
fragmented diffuse spike wave or polyspike wave discharges or frank 
generalised spike wave discharges. 
2.2. Evoked Potentials 
An evoked potential is an electrical manifestation of the brain’s 
reception of and response to an evoked stimulus. Evoked potentials have been 
studied in patients with neurological diseases since early 1950s but it was 
only in the early 1970s that evoked potentials began to have definite clinical 
utility. These tests provide sensitive and quantitative extensions of the 
clinical neurologic examination. Brainstem auditory evoked potential has 
earned a strong clinical reputation as a tool to evaluate the integrity of 
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auditory pathway from the external ear to lower brainstem and has been 
extensively used in patients with seizures. 
2.2.1. BAEP and epilepsy 
Epilepsy is a neurological disorder which is characterized by abnormal 
changes in the brain’s electrical potentials. The excessive neuronal 
excitability produced as a result of biophysical and biochemical cellular 
dysfunction alters the BAEP which is noted in various studies.  
-   Cranfor  JL  et  al128 has reported that central auditory impairment is 
present in bi-hemispheric seizure disorders. The patients have shown 
improvement in the measures of central auditory function following 
successful surgery to control epilepsy, but the results are prone to 
variability. 
-  Zhao JY et al analysed a Chinese family and proved that hearing loss 
associated with epilepsy is due to a mitochondrial mutation. He 
evaluated in clinical and genetic aspects along with sequential analysis 
of mitochondrial genome in a three generation Chinese family and 
identified that 7472 del C is likely to be a novel mitochondrial mutation 
associated with hearing loss in epilepsy patients. 
-  Rodin et al97 studied 80 epileptic patients and observed significantly 
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prolonged I-III and I-V IPLs and longer standard deviations as 
compared to the normal controls. He noted that the number of different 
seizure types in an epileptic patient was significantly related to the 
changes in latency but type and duration of seizure do not show any 
such correlation. 
-  Salah Soliman et al98 recorded auditory brain stem response and 
middle latency response in 49 epileptic patients. He found that a 
statistically significant number of epilepsy patients showed elevated 
ABR (30.1%) and MLR (40.7%) in spite of these patients having 
normal hearing sensitivity which was assessed by pure tone 
audiograms. He observed that threshold elevation was more frequent in 
patients with grandmal epilepsy when compared with temporal 
epilepsy patients reflecting poor response in the former group. 
Furthermore they also noted that chronicity of illness was significantly 
related to the elevated ABR and MLR thresholds in patients with 
grandmal epilepsy in contrast to temporal lobe epilepsy patients. 
-   Masayuki  Ohishi  et  al125 selected 114 epileptic patients –both males 
and females and recorded ABR in these patients. He observed that the 
female epileptic group showed longer I-V IPL than that of the controls. 
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-  Chayasirisobhon S, Rodin E et al studied the functions of brainstem in 
81 epileptic patients using BAEPs. He acknowledged that the epileptic 
patients had significantly longer latencies for all the wave components 
and IPLs, especially I-III, I-V than the normal controls. 
-  Usha Panjwani et al83 studied the effects of antiepileptic drugs on 
BAEPs in 32 female epileptic patients. They observed that drug free 
epileptics  had  shortened  wave  V  absolute  latency  and  I-V  IPL  as  
compared to normal controls. 
      The development in the field of recording evoked potentials is closely 
linked to the discovery of electricity. 
1752-Benjamin Franklin with his kite experiment charged his leyden jar by 
using kite during electrical storms and postulated the presence of two 
opposing forces of electricity that is positive and negative. 
1791- Luigi Galvani discovered that nerves were good conductors of 
electricity. 
1850-Helmholtz was able to measure conduction velocity of nerve in frog. 
1861- The method of electro diagnosis based on faradic and galvanic current 
was introduced by Erb. 
1875- The credit of making the first observation of electrical activity of brain 
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goes to Richard Canton, who reported that he had detected currents from 
electrodes placed on the skull of exposed brain in rabbits and monkeys. 
1929- Hans Berger recorded the first human electroencephalogram from the 
electrodes placed on scalp. 
1939- Davis was the first to record electric potentials on the human skull in 
response to auditory stimuli. The potentials were generated in the cortex with 
latencies that ranged from 50 to 500 ms. Some years later, thanks to 
computers, faster and shorter amplitude responses were recorded called as 
middle latency potentials between 10-80 ms. 
1967-Sohmer and Feimesser were the first to record BAEP initially and 
attributed their origin to brainstem structures37. 
1971-Jewett and Williston were the first to describe BAEP waveforms. 
1974-Hecox and Galambos showed that ABR could be used for threshold 
estimation in adults and infants. 
The clinical utility of evoked potentials is based on their ability to 
-  Demonstrate abnormal sensory system function when the history and 
/or neurological examination are equivocal. 
-  Reveal the presence of clinically unsuspected malfunction in a sensory 
system when demyelinating disease is suspected because of symptoms 
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and signs in another area of CNS. 
-  Help in defining the anatomic distribution of a disease process 
-  Monitor the changes objectively over time in a patient’s status 
        FIGURE 3:  Classification of evoked potentials 
 
 
 
 
 
                                       
              
 
Sensory evoked potentials are recorded from CNS following 
stimulation of sensory organs. For example visual evoked potentials are 
elicited by a flashing light or changing patterns on a monitor; AEPs by a click 
stimulus presented through the ear phone and tactile or somatosensory 
evoked potential elicited by tactile or electrical stimulation of a sensory or 
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mixed nerve in the periphery. All these potentials are reliable diagnostic tests 
providing an objective measure of function in their related sensory system 
and tracts. 
2.2.2. Brainstem Auditory Evoked Potential 
The ground work for recording BAEP was laid in early 1930s when the 
electronic amplifiers became available. In 1939, the electrical response to 
auditory stimuli was first observed in raw EEG. 
      Recording BAEP is a simple non-invasive way of evaluating hearing 
function and has been widely used for early detection of neural conduction 
irregularities in the auditory pathway. Technical advances have lead to more 
widespread use of BAEP in various fields like audiology, neurology, 
anaesthesiology and neonatology. 
      Bluestone CD et al had acknowledged in their study that a normal ABR 
finding does not guarantee hearing and not all normally hearing subjects have 
normal ABR findings40. 
      In spite of many advantages, BAEP equally has limitations- requires an 
experienced person to identify the waveforms accurately and the procedure is 
time consuming (Graham JM et al 2007)41. Development of sophisticated 
techniques like CT/MRI have limited the use of BAEP. 
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2.2.3. Principle of auditory evoked potential35  
 The evoked response audiometry is based on the principle that the 
bioelectric response which is evoked by a sound stimulus always tend to 
occur after the same time interval. 
       The auditory pathway extends from the middle ear structures through 
the eighth cranial nerve, the brain stem, and finally to the auditory cortex. 
Auditory  stimuli  either  in  the  form  of  clicks  or  pure  tones  can  be  used  to  
assess the integrity of the auditory pathway. 
       Thus the auditory evoked potential is obtained by presenting auditory 
stimuli to each ear resulting in a sequence of waveforms which bear a close 
relationship to the structures in the auditory pathway and enables relatively 
specific localisation in the auditory pathway, particularly in the eighth cranial 
nerve and the brainstem. From the time of onset of the sound stimulus, the 
auditory evoked transient response can be recorded up to 500 milliseconds. 
2.2.4. Classification of Brainstem auditory evoked potentials 
This tool of investigation which was first described by Jewett and 
Williston in 1971 can be classified as short, middle and long latency 
responses. 
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Short latency response 
      The normal Brainstem auditory evoked potentials occurring within first 
10 ms give unique information about the brainstem functions is called the 
early phase of transient response or short latency response. These potentials 
are well known as Brainstem Evoked Response Audiometry (BERA) or 
Brainstem Auditory Evoked Potentials (BAEP) and this has been utilised 
extensively by the clinicians. 
Advantages of BAEP include 
1.  This test is used to detect deafness in uncooperative patients like 
infants and mentally retarded or malingering individuals and can also 
be carried out correctly even in deeply sedated and anaesthetised 
patients. 
2. Objectively determines the nature of deafness (i.e. sensory or neural) in 
difficult to test patients especially when they cannot respond 
adequately to tests. 
3. Identification of the site of lesion in retro cochlear pathologies- The 
retro cochlear area is fairly a large area extending right from the spiral 
ganglion of the cochlear nerve to the midbrain (level of inferior 
colliculus). Unlike other tests used by the neurotologists which merely 
suspect whether any retro cochlear disease is present or not, BAEP 
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helps to identify the approximate area in the retro cochlear pathway 
where the lesion is present which is utilised in diagnosing conditions 
like acoustic neuroma with accuracy. 
4.  Study of central auditory disorders- Evoked response audiometry is 
useful in differentiating diseases of the auditory cortex from diseases 
of the more peripheral organs. 
5.  Helps to analyse the maturity of the central nervous system especially 
in new born, evaluating prognosis in comatosed patients, objective 
identification of brain death etc. 
Middle latency response (MLR) 
Auditory evoked potentials occurring before 10-50 msec is called  
MLR which reflects the activation of both subcortical structures(thalamus) 
and auditory cortices(mainly primary auditory cortex)42. 
Long latency response (LLR) 
This response arises from multiple cortical generator sources (Neshige 
et al1992)43 and have latencies greater than 50 msec distributed entirely over 
the scalp. 
 
 
 
 
FIGURE 4: Generators of auditory evoked potentials 
 
 
 
 
 
 
 
 
 
 
 
 
LLR      - Long latency response 
MLR     - Middle latency response 
BERA    - Brainstem evoked response audiometry 
AP       - Action potential 
CM      - Cochlear microphonics 
MGB    - Medial geniculate body 
IC       -Inferior colliculus 
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2.2.5. Anatomical and Neurophysiological basis of brainstem auditory 
evoked response audiometry37 
The sound pressure waves causes displacement of tympanic membrane 
which is transmitted through inner ear ossicles to the oval window. This 
causes movement of perilymph present in the scala vestibuli and tympani and 
secondarily of potassium rich endolymph contained in the ductus cochlearis 
and hence the basilar membrane, spiral organ and tectorial membrane are 
displaced. 
So the spiral organ containing the hair cells produce auditory receptor 
potentials when it is displaced by the movement of tectorial membrane. The 
receptor potentials tend to trigger action potentials in the dendrites of afferent 
nerve fibres of cochlear nerve due to the release of neurotransmitters. It is 
approximately estimated that 20000 to 30000 hair cells are scattered over a 
distance of 31.5mm in 2.5 spirals of cochlea. It is found that low frequency 
sounds activate the apical portion of cochlea and high frequency sounds 
generate receptor potentials in the basal portion. The click stimulus used in 
BERA contains mainly high frequency tones which stimulates the basal 
portion of cochlea. 
The cochlear nerve neurons situated in the spiral ganglia are bipolar 
with their dendrites in the hair cells and axons reaching the cochlear nucleus. 
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This cochlear nucleus has 3 sub nuclei components: 
1. Anterior ventral cochlear nucleus (AVCN) 
2. Posterior ventral cochlear nucleus (PCVN) 
3. Dorsal cochlear nucleus (DCN) 
The output of AVCN runs through the ventral acoustic striae forming 
the bulk of trapezoid body and terminates in the superior olivary nucleus and 
inferior colliculus. The neurons in AVCN tend to discharge at short latency to 
acoustic stimuli with a pattern similar to that of cochlear nerve. 
Most of the output of PVCN goes through the ventral and middle 
acoustic striae to terminate in the superior olivary nucleus and inferior 
colliculus. Through the dorsal striae, the dorsal cochlear nucleus terminates 
in the superior olivary nucleus and contralateral inferior nucleus. The 
discharge from these neurons have a longer latency thus differing from 
AVCN. 
The cochlear nucleus thus terminates in the superior olivary nuclear 
complex which includes 2 components-medial and lateral at the base of pons. 
The medial superior olivary nucleus receives excitatory inputs from both 
ipsilateral and contralateral AVCN. The lateral superior olivary nucleus also 
receives excitatory inputs from both ipsilateral AVCN and PVCN as well as 
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inhibitory inputs from contralateral AVCN and PVCN via) trapezoid body. 
From the olivary nucleus, the impulses travel to the ipsilateral and 
contralateral lateral lemniscus and to inferior colliculi. The olivary nuclei are 
the first site in the auditory pathways where the neurons are affected in a 
nonlinear manner to binaural stimulation. 
The lateral lemniscus nuclei and inferior colliculi converges the input 
from contralateral cochlear nucleus and superior olivary nucleus. The 
impulse from the inferior colliculi reaches the medial geniculate body where 
the neurons form the acoustic radiation of internal capsule finally synapsing 
in the Heschl gyrus of the primary auditory cortex (superior temporal gyrus 
and upper bank of sylvian fissure including the frontal and parietal opercula), 
the deeper mesial portion of which is activated by the high frequency tones 
like clicks used in BERA. 
The orderly orientation of the neurons in dorsal cochlear, medial 
superior olivary and lateral superior olivary nucleus results in summation of 
synaptic potentials to result in high amplitude electric fields. 
       The journey of the auditory impulses through this pathway generates 
an electric activity which can be recorded by placing surface electrodes on the 
scalp. This electrical activity is manifested as waveforms with discrete peaks 
in the BERA readings, the nature and character of which can be studied using 
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various parameters and this reveals the structural and functional integrity of 
the auditory pathway. 
Spiral ganglion in the cochlea àVentral and dorsal cochlear nuclei in 
the brainstem àSuperior olivary complex in the midbrain àLateral 
lemniscus in midbrain àInferior colliculus in midbrainàMedial geniculate 
body in thalamus àAuditory area in cortex. 
FIGURE 5: Auditory pathway 
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2.2.6. Normal Waveforms of BAEP 
There are 5 or more distinct waveforms recorded within 10millisec of 
auditory stimuli (Jewett DL et al 1971)44. The analysis of these waveforms 
with regard to latency, amplitude, wave morphology provides 
neurodiagnostic information on cochlear and retrocochlear auditory function. 
TABLE 1: Generators of BAEP waveforms 
WAVEFORM    GENERATORS 
I Eighth nerve(Cochlear nerve) 
II Cochlear nucleus 
III Superior olivary nucleus 
IV Lateral lemniscus 
V Inferior colliculi 
 
FIGURE 6: GENERATORS OF BAEP WAVEFORMS 
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2.2.7. Clinical applications 
-  Neil Bhattacharya53 demonstrated that these evoked potentials can be 
utilised as an effective screening tool in the evaluation of suspected 
retro cochlear pathology such as vestibular schwannoma or acoustic 
neuroma. 
-  Young G Bryan54 suggested  that  persistent  abnormalities  of  BAEPs  
reliably indicate the likelihood permanent vegetative state or death. 
-   J.K.Nousak  et  al55 showed that the BAEP latencies are accurate in 
evaluating hearing threshold. 
-  Studies carried out by Avasthi R Subhendu56 have identified an 
increase in absolute latencies of all the waves of BAEP in patients with 
advanced hypertension and following treatment significant decrease in 
the wave latencies were observed demonstrating their role in 
prognostic follow up of these patients. 
-  Kurita A et al57 compared 20 normal controls with diabetic patients and 
showed that diabetics had significantly longer latencies. 
-  Flint Boettcher A58 demonstrated that latencies were prolonged in 
presbyacusis and can be used as an evaluating tool in elderly 
individuals for early detection of hearing loss. 
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-   In  a  study  conducted  by  Ikuta  et  al59, he showed that differences in 
waveforms are seen in evoked potentials of schizophrenics, manic 
depressives and epileptics as compared to healthy adults. 
-  Atis et al60 recorded BAEP in patients with COPD and attributed the 
prolonged latencies to chronic hypoxic-hypercapnic status occurring in 
the brainstem. 
-  Schwarz G et al61 studied BAEP in patients with respiratory 
insufficiency following encephalitis and observed prolongation of all 
waves and IPL due to proximity of respiratory control centre in the 
brainstem. 
-   In  a  study  done  by  Reyes  Contreras  et  al62, he observed significant 
differences in I-V IPL in HIV infected patients as compared with 
controls and concluded that HIV infection may produce subclinical 
pathologic changes in the cochlear nerve and brainstem which can be 
recorded by BAEP recordings. 
-  Leocani et al63 in his study suggested that patients with multiple 
sclerosis can have abnormal ABRs. 
-  Lew and Henry L64 demonstrated that BAEP recording can serve as an 
objective tool for estimating hearing dysfunction in traumatic brain 
injury patients. 
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2.3. Cytokines 
They are low molecular weight regulatory proteins secreted by white 
blood cells and various other cells of the body in response to multiple 
stimuli65. In recent years an increasing body of evidence suggests that there is 
a complex relationship existing between epilepsy and immune system. 
      Plata  –Salaman  CR66 observed  abnormalities  in  the  expression  of  
cytokines and immune cells in patients with epilepsy. 
      Kalueff AV et al67 recognised that the immune system and its 
associated inflammatory reactions play an important role in the process of 
epileptogenesis.  
      Steffensen SC et al68 implicated cytokines as mediators of spontaneous 
seizures. 
      Fann MJ et al69 identified that these cytokines influence many central 
neurotransmitters including Noradrenaline, Gamma amino butyric acid, 
Acetyl choline, 5 Hydroxy tryptamine as well as the expression of various 
neuropeptides in several brain regions. 
2.3.1. Interleukin-1beta (IL-1β) 
IL -1β which is synonymous with catabolin is a cytokine protein 
encoded by the IL -β gene found on chromosome 2 in humans. IL- 1beta is a 
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pro inflammatory cyokine that activate additional cytokine cascade and 
enhances the susceptibility of seizures. IL 1 cytokines are regularly expressed 
at very low levels in human CNS (Ravizza T et al 2006)70. Seizures enhance 
the expression of IL- 1βand its mRNA as well as IL 1Ra mRNA (De Simoni 
MG et al 2000)71. Concentration of IL-1β in extracellular compartment is the 
prime factor for determining it functional actions in the brain. 
      IL 1β augment nitric oxide formation to raise the seizure susceptibility  
and also increase the neuronal excitability by directly inhibiting 
GABA(A)receptors, enhancing NMDA receptor function and inhibiting K 
efflux104. Viviani et al105 has shown that IL-1β increases the phosphorylation 
of the NR2B subunit of NMDA receptor thereby enhancing Calcium influx 
into the neurons. Through the activation of sphingomyelinase, IL-1β induces 
the production of ceramide which in turn activates the Src family tyrosine 
kinases leading to NR2B phosphorylation.  Balosso et al106 suggest that the 
activation of this pathway underlies the proconvulsant activity of IL-1beta. 
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FIGURE 7: Interleukin-1beta in epileptogenesis 
 
 
     
 
 
 
 
 
 
 
During epileptogenesis, strong IL-1β and IL-1R immunoreactivity was 
found also in perivascular astrocytic end feet impinging on blood vessels and 
in endothelial cells of microvasculature. Ravizza et al 2008 associated these 
changes  with  tissue  extravasation  of  serum  albumen.  IL-1β can  affect  the  
permeability properties of blood brain barrier by disruption of tight junctions 
or nitric oxide production along with activation of metalloproteinases in 
endothelial cells which result in chronic neuronal hyperexcitability. Further 
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alterations in BBB permeability may favour the entry of the cells of adaptive 
and innate immunity into the brain which perpetuates inflammation.  
Van illet et al 2006 proved that the extent of BBB damage positively 
correlates with the frequency of spontaneous seizures 
IL-1β is cleaved from precursor protein (pro IL-1β) by IL-1β 
converting enzyme (ICE) otherwise called as caspase 1. Black et al showed 
that this cleavage is essential for the formation of active form of IL-1β. 
Recently Ravizza et al has reported a novel anticonvulsant treatment strategy 
which inhibits IL-1β production in brain using ICE inhibitors resulting in 
reduced seizure duration as well as increased resistance to seizures in kainic 
acid models. 
Peltola et al92 suggests that the levels of various cytokines increase 
transiently in the blood and CSF of patients with epilepsy after different types 
of seizure and the cytokine concentration was found to higher in CSF than in 
blood suggesting a brain origin 
      Vezzani et al in his experimental studies identified that IL-1β prolong 
the duration of kainic acid induced seizures. 
      Rosenbaum KJ et al129 acknowledged that seizures themselves can 
activate the sympathetic nervous system and induce the release of 
catecholamine which mediates cytokine release from the peripheral blood 
mononuclear cells. 
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Lehtimaki et al101 have proved that that the levels of IL 1 beta, IL1ra 
and IL6 were transiently elevated after electrographic seizures. 
      Gang  Li  et  al  suggests  that  the  level  of  IL-1β,  IL-6  and  TNF  alpha  
increases quickly after either GTCS or complex partial seizures and return to 
baseline after varying time intervals. 
      S.Sinha, S.A.Patil, V.Jeyalekshmy et al91 analysed serum cytokine 
levels in 100 patients with epilepsy and new onset seizure in the immediate 
postictal phase. They observed a highly significant increase in serum levels of 
IL-1β, IL-2, 4, 6, TNF-alpha, IFN gamma in epilepsy patients as compared to 
the  controls.     
 
 
 
 
 
 
 
 
3. AIM & OBJECTIVES 
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3.  AIM AND OBJECTIVES 
The  aim  of  this  study  is  to  evaluate  the  Brainstem  auditory  evoked  
potential in patients with Generalised Tonic Clonic Seizures in comparison 
with age and sex matched controls. 
The objectives of the study were 
· To determine the functional integrity of auditory pathway in patients 
with GTCS by recording brainstem auditory evoked potential. 
· To assess serum Interleukin -1 beta levels in these patients. 
· To find the correlation between serum Interleukin-1 beta level and 
Brainstem auditory evoked potential in patients with Generalized 
Tonic Clonic Seizures. 
  
4. MATERIALS  
& METHODS 
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4. MATERIALS AND METHODS 
 
The study was conducted during the year 2013-2014 in the Institute of 
Physiology and Experimental Medicine, Madras Medical College after 
obtaining approval from the Institutional Ethics Committee, Madras Medical 
College Chennai. 
4.1 Patient selection 
Patients of both sexes in the age group between 20-40 years diagnosed 
as generalized tonic clonic seizures were included in the study. They were 
selected from the Institute of Neurology, Rajiv Gandhi Government General 
Hospital, Chennai - 3. 30 age and sex matched apparently healthy people 
were selected as controls. 
4.2   Inclusion criteria 
Thirty patients , both men and women in the age group of  20-40 years 
diagnosed as generalized tonic clonic seizures who were on treatment  were 
included in the study after confirming the normal hearing ability of these 
persons using pure tone audiogram. 
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4.3   Exclusion criteria 
 - Children and pregnant women 
 -  Patients with diabetes and hypertension 
-  Subjects with congenital hearing loss and sensorineural deafness 
-  Tumours like acoustic neuroma and meningioma 
-  Acute brainstem stroke 
-  Demyelinating diseases like multiple sclerosis 
-  Subjects with head injury and infections like meningitis and 
encephalitis 
-  Neurodegenerative diseases like dementia 
-  Febrile seizures 
-  Conditions that mimic GTCS like psychogenic nonepileptiform 
seizures 
-  Subjects with neoplastic, hepatic, respiratory and any cardiovascular 
disorder or other concurrent medical illness 
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4.4   Control group 
Thirty age and sex matched controls were selected from technicians, 
staffs and attenders of the patients. 
      With all these criteria, a total of 60 individuals were selected for the 
study. Out of these 30 were apparently normal and termed as controls and the 
remaining 30 persons were patients with GTCS who were called cases. 
Informed verbal and written consent was obtained from the participants after 
explaining the procedure.  
STUDY DESIGN:  Cross sectional study 
TYPE OF STUDY: Comparative study 
PLACE OF STUDY: Institute  of  Physiology  and  Experimental  Medicine,                                   
Madras Medical College, Chennai. 
      All subjects included in the study had no hearing deficit as reported 
after thorough ENT examination which includes pure tone audiometry. 
Specific ENT examination 
         Both the control and study group of individuals were subjected for 
specific ENT examination in the Upgraded Institute of Otorhinolaryngology, 
Madras Medical College, Chennai. 
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The ENT examination comprises of external ear examination, tuning 
fork tests which include Rinne’s test and Weber’s test, otoscopic examination 
of tympanic membrane, presence of any obstruction by wax and examination 
of throat and nose. In the presence of any external ear obstruction with wax, it 
is promptly removed by appropriate treatment before proceeding for pure 
tone audiometry. 
Pure tone audiometry72 
Both the normal controls and GTCS patients were subjected for pure 
tone audiometry in the Institute of ENT, Madras Medical College. 
This procedure is performed to 
i. Find out the hearing threshold of the subjects 
ii. To rule out any external or middle ear pathology (the integrity of 
conducting pathway 
Principle and method of pure tone audiometry 
      This is the most widely used method for measuring hearing acuity. A 
pure tone audiometer is an instrument that can deliver tones of variable 
frequencies and intensities to the ear by means of an earphone. The 
frequencies which are usually tested are at octave steps- 
125,250,500,1000,2000,4000 and 8000 Hz. The intensity can be increased or 
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decreased for each frequency and that can vary from 10 dB to 120 dB. Most 
audiometers used nowadays are calibrated to the international (ISO) standard 
level to obtain accurate results. 
Both air conduction and bone conduction can be measured by using 
this  instrument.  The ideal  frequency to start  with 1000 Hz,  a  series of  tone 
pips or short signals are presented at intensity above the patients suspected 
threshold and the patient is instructed to signal every time whenever he hears 
a sound, the intensity is reduced in steps of 10 dB until no sound is heard by 
the subject. Now again the intensity is increased in steps of 5 dB until half of 
the tonepips are consistently heard. From this the patient’s threshold for that 
frequency can be determined and thresholds for the remaining frequencies are 
then measured. In a similar way the bone conduction is measured by putting a 
receiver onto the mastoid bone. The sound emitted is transmitted to the 
cochlea by the bones of skull, thus bypassing the external and middle ear and 
this gives a measure of inner ear function. The results are interpreted as 
audiograms. 
      In audiometry, it becomes essential to eliminate the possibility that the 
test sound can be heard in the opposite ear for which masking should be 
applied to the better ear while testing the diseased ear if the difference in 
threshold is 40 dB or more. Similarly when testing the bone conduction 
threshold, the other  
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ear should always be masked because of the possibility of sound transmission 
through the bones of the skull. 
4.5 Brainstem Auditory Evoked Potential 
                Both  the  group  of  subjects  (normal  controls  and  patients  with  
GTCS) were subjected to the noninvasive assessment of hearing i.e.)  
Brainstem Auditory Evoked Potential ( BAEP). 
4.6 Apparatus for BAEP 
The apparatus setup for measuring Brainstem evoked response 
audiometry are set as per the “Recommended standards for the clinical 
practice of evoked potentials” introduced in Guideline 9A: Guidelines on 
evoked potential, by American society of Clinical Neurophysiology73. 
The basic apparatus for recording of auditory brainstem evoked 
responses is illustrated in the figure 
               
 
 
 
 
Figure 8: APPARATUS FOR BAEP 
 
 
Photo No.1: Computerised Neurostim-Medicaid systems for recording 
Brainstem auditory evoked potential 
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Pulse generator 
The stimulus which is either in the form of clicks or tone pips is 
transmitted to the ear through the transducer placed in the headphone or insert 
ear phone. 
Recording electrodes 
      In recording auditory evoked potentials, three electrodes – active, 
reference and ground are used which are placed in the respective sites of scalp 
as per the International 10-20 electrode placement system. Both needle and 
surface electrodes can be used for recording AEP but ideally surface 
electrodes are preferred because it makes the procedure painless with lesser 
chances of infection. 
      For better placement of electrodes the patient should be instructed to 
have a shampoo bath to make the hair oil free before coming for the 
investigation. 1 cm disc electrodes filled with conducing jelly or paste are 
used. The electrical impedance should be kept below 5 kilo ohms for better 
recording of AEP, if it is too high the skin should be again cleansed with 
acetone and the surface electrodes should be reapplied with electrolyte jelly 
or EEG paste. 
      The electrode on the vertex serves as the reference whereas active and  
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ground electrodes are placed on the ipsilateral and contralateral mastoid 
process respectively. 
Filter  
Filter is a device that restricts selectively the frequency domain of the 
signal. The filter band pass is the frequency range of a signal which is 
transmitted through the filter. The frequency range in which a signal is 
rejected is called stop band. Between the pass band and the stop band, lies the 
transition band which is the characteristic of the filter. Filtering of the 
neurophysiological signals is essential for noise elimination and optimizing 
the recording. It is also useful to bring out the typical characteristics of the 
wave forms, which may not be obvious otherwise. 
The low frequency filters remove the slowly changing low frequency 
components and permit the higher frequencies to pass through, therefore they 
are also called high pass filters. Similarly the high frequency filters tend to 
eliminate the rapidly changing high frequency components and allow the low 
frequency to pass through hence they are otherwise called as low pass filters. 
Amplifier  
      Because of the very small biological signals, a variable degree of 
amplification (upto 500000 times) is required equal to the range of Analog to 
digital converter. The electrode impedance includes intrinsic impedance of 
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the electrode and the impedance of electrode-skin interface. For the 
measurement of any electrical activity including action potential which is 
generated in CNS, nerve or muscle should flow through the electrode into the 
amplifier and return to the patient through the ground lead. Electrode 
impedance results in drop of the amplitude of the action potential. This 
attenuated action potential reaches the amplifiers. 
In order to reduce this attenuation, the impedance of the amplifiers 
should be much greater than electrode impedance. The electrode and 
amplifier and amplifier impedance both are inversely related to frequency. A 
100:1 ratio of electrode to amplifier impedance should be maintained across 
the range of frequencies contained in the waveform under study. This 
minimizes the distortion of waveforms and improves noise rejection. 
Unequal electrode impedance imbalances the electrode amplifier input, 
converting some of the noise into a different signal, which is amplified to the 
same extent as the neurophysiological signal.to reduce the 
impedance-induced noise, the active, reference and ground electrode 
impedance should be minimized. 
Signal averager 
The process of measuring the electrical activity of brain in response to 
sound stimuli given to the ear is a complicated manoeuver because some 
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amount of random and spontaneous electrical activity is continuously 
generated within the brain (also called background potential) and a recording 
of such electrical activity is termed as electroencephalography (EEG). So the 
electrical activity setup in the brain in response to the sound stimulus gets 
obscured by superimposing over the spontaneous electrical activity occurring 
in the brain. 
The magnitude of the electrical activity evoked by a sound stimulus is 
comparatively small i.e.) 1/100 of that of spontaneous random electrical  
activity. To distinguish these two types of electrical activity, a process called 
signal averaging is performed. This is based on the fact that evoked electrical 
activity is time specific which occurs at a fixed or specific point of time after 
the sound stimulation whereas the random electrical activity occurs randomly 
and not time specific. It is because of this fact we arrive at a point that if the 
electrical activity generated by a very large number of separate sound stimuli 
at a specific point of time is added together, only the electrical activity evoked 
by the sound stimulus will keep on adding whereas the background potential 
which occurs at random without any time specificity will cancel each other. 
Thus this signal averaging technique enables to get the uncontaminated 
measure of the sound evoked electrical activity without amplifying the 
responses. 
 
 
 
Photo No.2: Recording of Brainstem auditory evoked potential in 
 a normal volunteer  
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Electrical safety 
While recording BERA, care should be taken to ensure the safety of the 
patient. The grounding and chassis leakage current of all the instruments 
connected to the patient must be periodically checked and the equipment 
should be designed in such a way to prevent inadvertent shock during power 
on, power off and failures. 
4.7 Procedure of recording BAEP 
The subject is instructed to have a shampoo bath to make the hair oil 
free before coming for the investigation. The recording was carried out in a 
quiet  and  semi  darkened  room.  The  skin  at  the  point  of  placement  of  
electrodes was cleaned with spirit and cotton. Surface electrodes-active and 
ground are placed in the ipsilateral and contralateral mastoid processes 
respectively whereas the electrode on the vertex serve as the reference. 
The resistance was kept below 5 kilo ohms. Monoaural auditory 
stimulus consisting of rarefaction clicks of 100 microsec were delivered 
through electrically shielded ear phones at the rate of 11.1 clicks/sec. The 
contralateral ear was suitably masked by pure white noise of 40dB thus 
preventing false BAEP response. A band pass of 150-3000 Hz was used to 
filter out undesirable frequencies in the surroundings. Responses to 2000 
click presentations were averaged . 
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The result is obtained as a graph plotted with amplitude (in microvolts) 
on the ordinate and time (in ms from the onset of stimulus) on the abcissa. It 
consists of 5-7 waves or peaks within 8-10 ms and analysis of these 
waveforms with regard to latency, amplitude and morphology provides 
neurodiagnostic information on cochlear and retro cochlear function. 
FIGURE 9 : Recording of BAEP waveforms 
                 
Wave I 
This potential which is generated in the most peripheral portion of 8th 
CN corresponds to the compound AP recorded in electrocochleogram 
(Hashimoto I et al 1981)45. This prominent initial up going peak in the 
ipsilateral ear recording channel appears 1.4 ms after the stimulus and is 
attenuated or absent in the contralateral ear recording channel. 
Wave II 
      This wave is poorly defined and appears as a small peak along the down 
going slope of wave I or in the up going slope of wave III. It comprises of 2 
components  
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- APs in the intracranial portion of 8th CN which has been demonstrated 
by direct intra surgical recordings for the 8th nerve (Moller AR et al 
1988)46. 
- Potentials generated in the intra parenchymal afferent auditory 
pathways in the ipsilateral rostral medulla which has been confirmed 
by animal studies showing that trapezoid body exhibits prominent 
activity at the timing of wave II (Caird D et al 1985)47. 
Wave III 
This is usually a prominent peak which appears 3.9 ms after the click 
stimulus. Normal individuals may exhibit a bifid wave III in association with 
a normal I-V IPL. 
Wave IV 
This wave which occurs as a distinct and identifiable wave in 50-60% 
of the individuals is seen as a peak just preceding the wave V. 
Wave V 
It is the most prominent peak appearing 5.5 msec after the stimulus  
which is probably generated in the most lateral portion of lateral lemnisci or 
in inferior colliculi or in both. This wave component is analysed most often in 
clinical applications of ABR. In unilateral mesencephalic lesions, this wave is 
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consistently attenuated or even absent (Markand ON et al 1989)48 during 
ipsilateral ear stimulation which has been demonstrated in many clinical 
studies. 
Wave VI and VII 
The origin of these waves are poorly defined and they are reasonably 
assumed to be generated from subcortical structures like MGB and auditory 
radiation with average latencies of 7.3 and 9.6 ms respectively. Depth 
electrodes placed in MGB show a positive peak at the time of wave VI. 
4.8 Interpretation of waveforms 
     The parameters taken into consideration for studying the waveforms of 
BAEPs are 
1. Absolute latency and amplitude 
2. Inter peak latencies 
3. Amplitude ratio of wave V/I 
4. Inter ear inter peak difference 
Absolute latency 
Latency of a wave is the time interval which is measured in ms from 
the onset of stimulus to the peak of the wave. As absolute latencies are 
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affected by non-pathological factors, they are not reliable. The absolute 
latency of wave V is valuable for clinical purposes since it is the wave most 
commonly present and easily identifiable. 
Absolute amplitude 
This is measured as the height from the peak of the wave to its trough 
expressed in microvolts and their values are highly variable to be of any 
clinical significance because amplitude of the waves is not as constant as 
latency. 
Inter peak latency (IPL)  
       The time interval between two different waves in the same ear is called 
inter peak latency which is otherwise called as inter wave latency. The IPLs 
commonly measured are  
1. I-III IPL 
       It  is  represented by normal value of  about  2.5 ms which reflects  the 
conduction time between cochlea and the core of lower pons. 
2. I-V IPL 
This IPL is an index of the conduction time between the cochlea and 
proximal part of cochlear nerve and the midbrain through pons, the normal 
value of which is 4.5msec. 
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3. III-V IPL 
       The isolated prolongation of this IPL is not significant which measures 
the conduction from caudal pons to midbrain. 
4. Amplitude ratio of wave V/I 
       This ratio compares the relationship of the signal amplitude since the 
wave I is generated outside and wave V is generated inside the CNS. The 
normal ratio varies between 50-100%. If the ratio exceeds 300%, it indicates 
peripheral hearing impairment but if it is less than 50%, then it implies 
significant central hearing loss. 
5. Inter ear latency difference 
       When the same amount of supra threshold sound stimulus has been 
given to both the ears, it is the time interval between the 2 ears of the same 
wave which should not be more than 0.5msec. 
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TABLE 2: Normal waves of BAEP 
WAVES 
(latency ms) 
Misra and Kalita et al37 
n=30 pts ;15-68years 
Chiappa et al39 (1979) 
I 1.67±0.17 1.7 ±0.15 
II 2.78±0.21 2.8±0.17 
III 3.65±0.22 3.9±0.19 
IV         5.0±0.30 5.1±0.24 
V         5.72±0.3 5.7±0.25 
VI         7.2±0.48 7.3±0.29 
I-III IPL 1.99±0.25 2.1±0.15 
I-V IPL 2.08±0.30 1.9±0.18 
III-V IPL 4.04±0.25 4.0±0.23 
                                
Factors that tend to affect BAEP are  
1) Technical factors 
A. Stimulus rate 
The number of clicks presented to the ear in each second is defined as 
the stimulus rate. The normal recommended rate is 10-40 clicks /sec. As the 
stimulus rate becomes high, the amplitude and absolute latency of the waves 
show opposite changes i.e.) amplitude reduces whereas the latency increases. 
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B. Intensity of the sound stimulus. 
At higher stimulation intensities, wave I often decreases at a slightly 
faster rate, resulting in relatively more prolonged I-V IPL. With decreasing 
click intensities all the waves except I, III, and V are likely to disappear. With 
even lower click intensities, only peak V may persist which may be seen with 
click intensities as low as 10 dBSL.  
       Also Elberling et al observed that the increase in wave V latency is not 
linear, with a relative acute change in latency occurring between 40 and 
60dBSL clicks. This is one of the reason stimulation intensities of at least 70 
dBSL are recommended for routine BERA studies in clinical practice. 
C.Stimulus phase or polarity 
The  phase  or  polarity  of  the  click  stimulus  can  be  of  2  
types-condensation phase and rarefaction phase. The transducer of the BERA 
machine has got a diaphragm which vibrates i.e.) move outwards and inwards 
to produce the click sound. 
       When the diaphragm moves initially outward i.e.) towards the 
eardrum, the phase is termed as condensation phase whereas if it moves 
inward i.e.) in a direction away from the eardrum, it is known as rarefaction 
phase. This rarefaction phase is recommended for all routine BERA studies 
because of its capability to produce better resolution of the waves. Some 
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neurologists prefer using an alternating phase where rarefaction and 
condensation phases alternate closely with each other. If the condensation or 
alternating phase is used, the absolute latencies of all the waves I, II, III, IV 
are increased except wave V which is not that much altered by the phase 
change. 
4. Filter characters of the machine 
The BERA machine is adjusted in such a way that it records only a 
fixed range of frequencies which has a lower and higher limit. The lower 
frequency filter should be 100 or 150 Hz whereas the high frequency limit is 
usually kept at 3000 Hz and this is termed as filter settings of the machine. 
       Frequencies lower than 100 Hz and higher than 5000 Hz should be cut 
off to reduce the artefacts which may interfere with the BERA readings. So 
altering the filter settings can introduce artefacts and also change the 
amplitude ratios of the waves. 
5.  Nature of sound used 
The sound stimulus used is a click sound produced by the transducer 
for eliciting auditory evoked potentials which is generated as a square wave 
pulse of 0.1msec duration each. The sound pressure wave which was 
generated by this stimulus can be displayed on an oscilloscope and consists of 
an initial major wave followed by highly damped oscillations of alternating 
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polarity that may last up to 2msec or longer. To obtain clearly recognisable 
and distinct waves, the sound stimuli are delivered at 50-60 db above the 
hearing threshold. Sometimes pure tone sound stimulus (tone pips) are used 
which presents with morphologically poor waves. 
6.  Binaural/monaural stimulation 
Monaural stimulation is recommended in clinical studies but if the 
sound stimulus is presented to both ears simultaneously ,then the amplitude 
of the waves III, IV, V are increased but not wave I. 
2)  Nontechnical factors 
A. Age 
Age has a distinct effect on BAEP waveforms. Starr et al49 observed 
longer BAEP wave latencies in infants when compared to adults which is 
ascribed to slower axonal conduction. 
       Jerger  and  Hall50 experimentally noted these differences in 1980 when 
they examined the latencies in 70 normal subjects. 
       Stockard et al observed that the waveforms in infants are often higher 
in amplitude than in adults presumably on the basis of smaller head size and 
greater proximity of recording electrodes to BAEP generators. 
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Rowe et al107 demonstrated in his study that selective prolongation of I-III 
IPL occurs in presbyacusis. 
B. Gender 
The difference in head size can be correlated to the significant 
difference of the wave components between males and females. The 
amplitude  of  all  waves  is  found  to  be  higher  in  a  significant  proportion  of  
females whereas consistent prolongation of absolute latency of wave V and 
I-V IPL are noted in males. 
TABLE 3: Gender differences in normal BAEP waveforms 
Wave Taghavy &Losslein et al51 Pedialli et al 200452 
 Males Females Males Females 
I 1.64±0.16 1.59±0.09 1.42±0.06 1.44±0.10 
II 2.83±0.19 2.75±0.12   
III 3.91±0.20 3.67±0.15 3.61± 0.13 3.59± 0.09 
IV 5.14±0.25 4.97± 0.17   
V 5.80±0.20 5.52± 0.15 5.54± 0.21 5.32± 0.13 
I-III 2.27± 0.20 2.08± 0.13 2.18±0.13 2.12±0.11 
I-V 4.18±0.24 3.90±0.19 4.11±0.21 3.88±0.17 
III-V 1.90±0.19 1.85±0.14 1.93±0.14 1.75±0.12 
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C.Temperature 
With decreasing central body temperature, the latencies of BAEPs are 
increased. Latencies increase roughly 7% for each 1 Celsius. As the 
temperature reduces down to 27-28 C, the amplitude of BAEPs initially 
increases but then it drops down linearly with temperature drop and finally 
disappears at 20 degree C. 
D. Hormonal effects 
Yadav et al studied BAEP latencies in 20 women with normal cycles in 
4 different phases and showed that there is a trend of increase in peak 
latencies of wave III and V in oestrogen-peak midcycle while decrease in 
latencies in progesterone-peak midluteal phase. These findings suggest that 
normal cyclical variations in the levels of oestrogen and progesterone during 
menstrual cycle do affect the auditory pathways and effects are better seen on 
the central component. 
E.Drugs 
       BAEPs are resistant to the effect of drugs, but a slight prolongation of 
wave V latency with barbiturates or alcohol is attributed to the lowering of 
body temperature. Effects of aminoglycoside antibiotics on BAEP 
waveforms was studied with the idea of developing a means of following the 
ototoxicity of these drugs by Guerit et al in 1981 and they found that the 
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minor latency changes noted disappeared with cessation of medication.  
4.9 Terminologies used in evoked potential study 
1. Decibel (dB=1/10 Bel) 
It is defined as ’20 log (P1/P2)’, where P1 is the intensity of the sound 
which is to be measured and P2 is the intensity of the reference sound. 
2. Sound pressure level(spl): 
It is the weakest sound heard by the most sensitive ear which is the 
standard physical reference for sound (20 micropascals or 0.0002 dynes per 
cm2). 
3. Hearing level: 
       Zero dBHL corresponds to the average hearing threshold of a group of 
normal hearing young adults in an ideal listening environment. 
4. Sensory level: 
       This expresses the intensity of a sound as a function of the hearing 
threshold for an individual ear for any given subject. 
4.10 Parameters studied 
       BAEP threshold for each ear with absolute latencies of waves I, III, V 
and IPLs of I-III, I-V and III-V were considered from the recording for 
comparison among GTCS patients and controls. 
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4.11 Summary of BAEP settings in our study 
1. APPARATUS: Neurostim, Medicaid systems 
2. ELECTRICAL MONTAGE:  L:Cz-A1 
                                 R:Cz-A2  
                                 Ground:Fz  
3.  AMPLIFIER:        Low  filter-100  Hz  
                       High  filter-3000  Hz  
4. ANALYSIS TIME: 10 milliseconds 
5. NUMBER OF EPOCS: 2000 trials with two repetitions 
6. STIMULATION: 
a. Nature of the stimulus to the test ear: 
            Broadband click of 100 micro seconds duration 
            Intensity  -80  dB  
            Stimulus rate-11.1 clicks per second 
b. Masking of contralateral ear:  By white noise of 50-60 dB is used 
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4.12 Estimation of Serum Interleukin-1 beta 
Under strict aseptic precautions, blood samples were collected from 
the ante cubital vein by means of venepuncture within 24 hours of the 
previous seizure episode and the separated serum was stored in deep freezer 
at -20 centigrade. Estimation of serum interleukin 1 beta levels was carried 
out in the Department of Experimental medicine, The Tamil Nadu Dr. 
M.G.R. Medical University. 
       Human IL-1β ELISA (Enzyme linked immunosorbent assay) kit is an 
in vitro enzyme linked immunosorbent assay for the quantitative 
measurement  of  IL-1β in  serum,  plasma and  cell  culture  supernatants.  The  
minimum detectable dose of IL-1β is typically less than 0.3 pg/ml. 
Reagent preparation 
1. Preparation of standard 
Briefly spin the vial containing recombinant human IL- 1 beta to which 
880microl of assay diluent A (0.09% sodium azide) is added to prepare a 
20ng/ml standard. The powder is dissolved thoroughly by a gentle mix. Then 
5 µl of IL-1 beta standard is added into a tube with 995 µl assay diluent A to 
prepare a 100 pg/ml stock standard solution. Use the standard stock solution 
for pipetting 200 microliter into each tube to produce a dilution series. 
 
 
Photo No. 3: Interleukin-1β kit and serum samples, ELISA reader in TN Dr. 
M.G.R. Medical University 
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2. Wash concentrate(20x) 
20 ml of wash buffer concentrate is diluted with distilled water to yield 
400 ml of 1xwash buffer. 
3. Detection antibody IL-1β (biotinylated anti human IL-1β) 
       100 µl of 1x assay diluent B (5x concentrated buffer) is added into the 
detection antibody vial to prepare a detection antibody concentrate which 
should be again diluted 80 fold with the same diluent. 
4. HRP –streptavidin solution 
       HRP –streptavidin concentrate should be diluted 300 fold with 1x 
assay diluent B. 
Assay procedure 
This assay employs an antibody specific for human IL-1 beta coated on 
a 96 well plate. 
1. 10 µl of each standard and sample are added into appropriate wells 
which is covered well and incubated for 2.5 hours at room temperature. 
2.  The  solution  is  discarded  and  washed  4  times  with  300microl  of  1x  
wash buffer. 
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3. 100 µl of prepared biotinylated antibody is added to each well and 
incubated for 1 hour at room temperature with gentle shaking. 
4. The solution is discarded and the wash procedure is repeated. 
5. 100 µl of prepared streptavidin solution is added to each well and 
incubate for 45 min at room temperature. 
6.  Discard the solution and repeat the wash as described above. 
7.   100 µl  of  TMB one step substrate reagent  is  added to each well  and 
repeat the incubation for 30 min at room temperature in the dark. 
8.  Finally 50 µl of stop solution (0.2 M sulfuric acid) is added to each well 
and read at 450 nm immediately in a ELISA reader. 
9. A standard graph is constructed by marking the average values of 
absorbance of each reference standard in the Y axis versus its 
corresponding concentration in X axis. 
10. The corresponding IL- 1β was obtained by simple interpolation from 
this standard curve. 
11. Average % was obtained by dividing observed value by expected 
value. 
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4.13 Statistical analysis 
Statistical analysis was done using the software SPSS version 21. 
1.  Student  ‘t’  test  was  carried  out  to  compare  the  means  of  variables  
between GTCS patients and normal subjects. 
2.  Pearson’s coefficient was done to find the correlation between serum 
Interleukin-1β level and BERA in GTCS patients. 
  
5. RESULTS
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5. RESULTS 
All the GTCS patients and controls enrolled for the present study had 
clinically no evidence of hearing deficit. 
5.1 Characteristics of study and control subjects 
Our study population consists of 30 GTCS patients (15 males and 15 
females) in the age group 20-40 years without any clinical evidence of 
hearing impairment. The control subjects were 30 in number with 15 males 
and 15 females belonging to the age ranging from 20-40 years. The mean age 
was calculated to be   30.86±2.54 years in the control group and the mean 
age of GTCS patients was found to be 30.86±2.54 years. The duration of the 
disease ranges from 1-2 years. 
5.2 Brainstem auditory evoked potential parameters 
Variables pertaining to BERA between normal and GTCS patients are 
given in the tables 4-17 and also represented in graphs 1-10. Among the 
BERA parameters, the absolute latencies of wave I, III, V and IPL I-III, I-V, 
III-V are utilized for evaluating the integrity of auditory pathway. 
5.3 Levels of Interleukin-1 beta 
        The  difference  in  the  mean  values  of  IL-1β between  controls  and  
GTCS patients are given in table 18 and graph 11. 
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TABLE 4: Age distribution in controls and GTCS patients 
 
 NUMBER MEAN ±SD ONE WAY ANOVA 
GTCS FEMALES 15 30.2±4.79 
F =2.34 
CONTROLFEMALES 15 29.06±4.97 
GTCS MALES 15 32.33±2.63 
CONTROL MALES 15 32.66±4.62 
TOTAL 60  
 
p value =0.082,  not significant. 
 
 
 
           TABLE 5: BMI distribution in controls and GTCS patients 
 
 NUMBER MEAN ±SD ONE WAY ANOVA 
GTCS FEMALES 15 23.80±1.28 
F =1.39 
CONTROLFEMALES 15 23.98±0.83 
GTCS MALES 15 24.65±1.73 
CONTROL MALES 15 24.54±1.09 
TOTAL 60  
 
P  value  =0.25,  not  significant                      
 
 
 
 
 
GRAPH 1: Age distribution in controls and GTCS patients 
 
GRAPH 2: DMI distribution in controls and GTCS patients 
 
GRAPH 2: BMI distribution in controls and GTCS patients 
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TABLE 6: Comparison of mean values of absolute and interpeak 
latencies between genders in the right ear of GTCS patients 
 
WAVES 
FEMALES MALES 
T TEST P VALUE 
MEAN ± SD MEAN ± SD 
I 1.60 ±0.21 1.61 ±0.15 0.15 0.88 
III 3.85 ±0.23 3.76 ±0.30 1.51 0.14 
V 5.67 ±0.17 5.59 ±0.19 1.21 0.23 
I-III 2.25 ±0.31 2.14 ±0.35 0.91 0.37 
I-V 4.07 ±0.17 3.97 ±0.27 1.21 0.23 
III-V 1.82 ±0.25 1.83 ±0.20 0.12 0.90 
 
p value-not significant for all the parameters 
 
TABLE 7: Comparison of mean values of absolute and interpeak 
latencies between genders in the left ear of GTCS patients 
  
WAVES 
FEMALES MALES 
T TEST P VALUE 
MEAN ± SD MEAN ± SD 
I 1.69 ±0.12 1.60 ±0.15 1.81 0.08 
III 3.95 ±0.20 3.83 ±0.27 1.38 0.17 
V 5.71 ±0.14 5.67 ±0.14 0.78 0.44 
I-III 2.26 ±0.23 2.23 ±0.39 0.25 0.79 
I-V 4.02 ±0.16 4.06 ±0.26 0.50 0.61 
III-V 1.75 ±0.26 1.83 ±0.20 0.94 0.35 
 
p value-not significant for all the parameters 
 
 
 
GRAPH 3: Comparison of mean values of absolute and interpeak latencies 
between genders in the right ear of GTCS patients 
 
GRAPH 4: Comparison of mean values of absolute and interpeak latencies 
between genders in the left ear of GTCS patients 
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TABLE 8: Comparison of mean values of absolute and interpeak 
latencies between genders in the right ear of control group 
 
WAVES 
FEMALES MALES 
T TEST P VALUE 
MEAN ± SD MEAN ± SD 
I 1.64 ±0.14 1.70±0.20 0.96 0.34 
III 3.67 ±0.14 3.72 ±0.18 1.38 0.17 
V 5.47 ±0.21 5.64±0.19 2.30 0.02 
I-III 2.03 ±0.19 1.96 ±0.26 0.84 0.40 
I-V 3.83 ±0.27 3.89 ±0.22 0.66 0.51 
III-V 1.81 ±0.25 1.89 ±0.14 1.08 0.29 
 
Wave V, p value = 0.02, significant   
The mean value of wave V absolute latency is significantly higher in males as 
compared to females in the right ear of control group. 
 
TABLE 9: Comparison of mean values of absolute and interpeak 
latencies between genders in the left ear of control group 
  
WAVES 
FEMALES MALES 
T TEST P VALUE 
MEAN ± SD MEAN ± SD 
I 1.65 ±0.16 1.69 ±0.19 0.62 0.53 
III 3.68 ±0.22 3.70 ±0.23 0.24 0.81 
V 5.46 ±0.26 5.59 ±0.25 1.39 0.17 
I-III 2.03 ±0.25 2.02 ±0.15 0.13 0.89 
I-V 3.80 ±0.33 3.89 ±0.33 0.74 0.46 
III-V 1.77 ±0.29 1.89 ±0.36 1.005 0.32 
 
p value –not significant for all the parameters 
 
 
GRAPH 5: Comparison of mean values of absolute and interpeak latencies 
between genders in the right ear of control group 
                                
GRAPH 6: Comparison of mean values of absolute and interpeak latencies 
between genders in the left ear of control group   
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TABLE 10: Comparison of mean values of absolute latencies between 
GTCS females and control females in the right ear. 
 
WAVES 
STUDY 
GROUP 
CONTROLGROUP 
T TEST P VALUE 
MEAN ± SD MEAN ± SD 
I 1.60 ±0.21 1.64 ±0.14 0.46 0.64 
III 3.85 ±0.23 3.67 ±0.14 2.58 0.015 
V 5.67 ±0.17 5.47 ±0.21 2.86 0.007 
 
Wave III, p value=0.015, significant 
Wave V, p value=0.007, highly significant 
 
The mean values of wave III and V absolute latency are significantly higher 
in GTCS females when compared to control group. 
 
TABLE 11: Comparison of mean values of interpeak latencies between 
GTCS   females and control females in the right ear 
 
   IPL  
STUDY 
GROUP CONTROLGROUP T TEST P VALUE 
MEAN ± SD MEAN ± SD 
   I-III 2.25 ±0.31 2.03 ±0.19 2.34 0.02 
   I-V 4.07 ±0.17 3.83 ±0.27 2.9 0.006 
III-V 1.82 ±0.25 1.81 ±0.25 0.11 0.91 
 
I-III IPL, p value=0.02, significant 
I-V IPL, p value=0.006, significant 
The mean values of IPL I-III and I-V are significantly higher in GTCS 
females when compared to control group 
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TABLE 12: Comparison of mean values of absolute latencies between 
GTCS females and control females in the left ear 
 
WAVES 
STUDYGROUP CONTROLGROUP 
T TEST P VALUE 
MEAN ± SD MEAN ± SD 
I 1.69 ±0.12 1.65 ±0.16 0.77 0.44 
III 3.95 ±0.20 3.68 ±0.22 3.51 0.001 
V     5.71 ±0.14 5.46 ±0.26 3.27 0.002 
 
Wave III, p value=0.001, highly significant 
Wave V, p value=0.002, significant    
The mean values of wave III and V absolute latencies are significantly higher 
in GTCS females as compared to control females. 
TABLE 13: Comparison of mean values of interpeak latencies between 
GTCS females and control females in the left ear 
  
IPL 
STUDYGROUP CONTROLGROUP 
T TEST P VALUE 
MEAN ± SD MEAN ± SD 
I-III 2.26 ±0.23 2.03 ±0.25 2.62 0.01 
I-V 4.02 ±0.16 3.80 ±0.33 2.32 0.02 
 III-V 1.75 ±0.26 1.77 ±0.29 0.19 0.84 
 
I-III IPL, p value=0.01, highly significant 
I-V IPL, p value=0.02, significant 
The mean values of I-III and I-V IPL are significantly higher in GTCS 
females when compared to controls. 
 
 
 
GRAPH 7: Comparison of mean values of absolute and interpeak latencies 
between GTCS females and control females in the right ear 
 
GRAPH 8: Comparison of mean values of absolute and interpeak latencies 
between GTCS females and control females in the left ear 
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TABLE 14: Comparison of mean values of absolute latencies between 
GTCS males and control males in the right ear 
 
WAVES 
STUDY 
GROUP 
CONTROLGROUP 
T 
TEST 
P VALUE 
MEAN ± SD MEAN ± SD 
I 1.61 ±0.15 1.70 ±0.20 1.39 0.17 
III 3.76 ±0.30 3.72 ±0.18 0.44 0.66 
V 5.59 ±0.19 5.64 ±0.19 0.72 0.47 
 
p value – not significant for all parameters. 
TABLE 15: Comparison of mean values of interpeak latencies between 
GTCS males and control males in the right ear  
 
IPL 
STUDY 
GROUP 
CONTROLGROUP T 
TEST 
P VALUE 
MEAN ± SD MEAN ± SD 
I-III 2.14 ±0.35 1.96 ±0.26 1.59 0.12 
I-V 3.97 ±0.27 3.89 ±0.22 0.88 0.38 
III-V 1.83 ±0.20 1.89±0.14 0.95 0.34 
 
p value – not significant for all parameters. 
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TABLE 16: Comparison of mean values of absolute latencies between 
GTCS males and control males in the left ear 
 
WAVES 
STUDY 
GROUP 
CONTROL 
GROUP T 
TEST 
P VALUE 
MEAN ± SD MEAN ± SD 
I-III 2.23 ±0.39 2.02 ±0.15 1.94 0.06 
I-V 4.06 ±0.26 3.89 ±0.33 1.56 0.12 
III-V 1.83 ±0.20 1.89 ±0.36 0.56 0.57 
 
p value – not significant for all parameters. 
 
TABLE 17: Comparison of mean values of interpeak latencies between 
GTCS males and control males in the left ear 
 
IPL 
STUDY 
GROUP 
CONTROL 
GROUP T 
TEST 
P VALUE 
MEAN ± SD MEAN ± SD 
I-III 2.23 ±0.39 2.02 ±0.15 1.94 0.06 
I-V 4.06 ±0.26 3.89 ±0.33 1.56 0.12 
III-V 1.83 ±0.20 1.89 ±0.36 0.56 0.57 
 
p value – not significant for all parameters. 
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GRAPH 9: Comparison of mean values of absolute and interpeak latencies 
between GTCS males and control males in the right ear 
 
GRAPH 10: Comparison of mean values of absolute and interpeak latencies 
between GTCS males and control males in the left ear 
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GRAPH 11: Comparison of serum inteleukin-1  
beta levels in controls and GTCS patients 
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TABLE 19: Correlation between IL-1 beta levels and ABR wave III in 
the right ear of GTCS patients 
 
 
 
CORRELATION 
BETWEEN 
IL-1BETA AND  
BERA WAVE III 
(RIGHT EAR) 
CORRELATION              
COEFFICIENT 
INTERPRETATION 
 
    r   =   -0.10  
 
Negative correlation 
 
    p   =   0.59  
 
Not significant 
 
 
TABLE 20: Correlation between IL-1 beta levels and ABR wave III in 
the left ear of GTCS PATIENTS 
 
 
CORRELATION 
BETWEEN 
IL-1BETA AND  
BERA WAVE III 
(LEFT EAR) IN 
GTCS PATIENTS 
CORRELATION           
COEFFICIENT 
INTERPRETATION 
r   =   0.049  
Weak positive 
correlation 
p   =   0.79  Not significant 
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TABLE 21: Correlation between IL-1 beta levels and ABR I-III IPL in 
the right ear of GTCS patients 
 
 
CORRELATION 
BETWEEN 
IL-1BETA AND  
BERA I- III (RIGHT 
EAR) IN GTCS 
PATIENTS 
CORRELATION           
COEFFICIENT 
INTERPRETATION 
r   =   -0.18  Negative  correlation 
p   =   0.32  Not significant 
 
 
TABLE 22: Correlation between IL-1 beta levels and ABR I-III IPL in 
the left ear of GTCS patients 
 
CORRELATION 
BETWEEN 
IL-1BETA AND  
BERA I- III (RIGHT 
EAR) IN GTCS 
PATIENTS 
CORRELATION           
COEFFICIENT 
INTERPRETATION 
r   =   0.03  
Weak positive 
correlation 
p   =   0.83  Not significant 
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6. DISCUSSION 
All  the  GTCS  patients  and  controls  included  in  the  study  were  
subjected to Brainstem auditory evoked potential for evaluating the integrity 
of auditory pathway. 
6.1 Characteristics of study subjects  
The mean age of GTCS patients included in the study was 30.1±3.11 
years. The mean age of GTCS patients in various studies (Usha Panjwani et al 
1996, Salah Soliman 1993) are almost similar to that of the present study. 
Thus the patients in the present study are in the adult group. Beagley et al and 
Anias et al observed no age related effect on absolute latencies. Therefore it 
could be stated that any abnormalities of BERA observed in the patients can 
be attributed to GTCS rather than age related causes.  
The duration of disease in GTCS patients of our study ranges from 1-2 
years and these patients were on treatment since diagnosed.  Soliman, Saad 
and Haaza74  observed poor resolution of ABR components and tend to 
correlate their findings with chronicity of the disease and the possible effects 
of antiepileptic drugs.  
       Salah  Soliman98 et  al  showed  that  chronicity  of  epilepsy  was  
positively related to the elevated auditory brainstem response and middle 
latency response thresholds in grandmal epilepsy patients. Many antiepileptic 
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drugs produce prolonged absolute latencies and interpeak latencies when 
administered for a long time. This is in agreement with previous studies of 
Chan et al75 and Green et al108. 
The BMI of the GTCS patients was found to be 23.68±1.61. Haslam et 
al76 and Landau et al77 demonstrated that the hypoxic adipose tissue tend to 
produce inflammatory cytokines; this inflammation results in imbalance 
between free radical production and its scavenging mechanisms resulting in 
damage to the neuron and surrounding schwann cells by associated oxidative 
stress and hence proving obese individuals are prone to develop early damage 
to auditory nerve. 
       In the present study, the analysis revealed that there was a significant 
difference in wave V latency time between the sexes; latencies were higher in 
the right ear of males when compared to females. This finding is consistent 
with various published data by Costa Neto et al, Hassan et al and Macedo et 
al. 
       Masaru Aoyagi et al78 proved that head size which reflects brain size is 
one of the determining factor for the basis of such gender differences. 
       Taghavy A and Losslein H et al51 in their study described that absolute 
latency, interpeak latencies and amplitude of waveforms of BERA were 
88 
 
significantly shorter in females than males. Inter aural differences of the same 
were negligible. 
       According to Edmir Americo Louenco et al126, the absolute latencies 
of ABR waves were higher in males, whereas the interpeak intervals showed 
no gender differences and the I-III IPL presented the higher incidence of 
alterations. 
       Stockard   et al79 demonstrated experimentally that females have 
shorter latency which is attributed to higher core body temperature and 
shorter length of brainstem auditory pathway. 
       Kellaway  et  al80 (1979) observed in women that the auditory evoked 
potentials show shorter absolute and interpeak latencies and their EEG has a 
high frequency of the occipital alpha rhythm. 
       Allison  et  al81 (1983) suggested that the length of brainstem auditory 
pathway varies as the cube root of brain volume and correlating thus with age 
and sex related variations in brain weight and calculated that the male female 
ratio should be 1.034+0.0008. When this is compared with normal data, 
latency sex difference were within normal limits. 
       Sturzebecher E and Werbs M127, 1987 found that the latencies of 
waves of waves I, III & V as well as the interpeak latencies I-V and III-V are 
significantly shorter in females than in males. 
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       Del  Pozo  82(1982) measured the distance between the cochlear nucleus 
and inferior colliculus in fresh post-mortem specimens; he did find it longer 
in men, although differences were not statistically significant. 
6.2  Brainstem auditory evoked potential  
Brainstem auditory evoked potentials reflect the neural activity from 
the cochlea to temporal cortex and they have been used successfully in 
clinical practice as an objective means for hearing threshold measurements as 
well  as  in  the  diagnosis  of  site  of  lesion  in  the  central  auditory  nervous  
system. 
Epilepsy is a neurological disorder characterised by abnormal changes 
in the brain’s electrical potentials. In other words, it can be described as 
cellular level dysfunction leading to excessive neuronal excitability as a 
result of biophysical and/or biochemical dysfunction. Accordingly auditory 
evoked potentials are expected to be altered by such dysfunction. 
       Various studies by Faught et al, Hughes et al, Mervaala et al and Rodin 
et al have indicated a large variability of AEPs in epileptic patients with 
various types of epilepsy when compared to normal population. 
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6.2.1. Wave I 
In the present study, the mean absolute latency of wave I is not found to 
be statistically significant in both right and left ears of male as well as female 
GTCS patients when  compared to controls (1.61±0.15 vs 1.70±0.20 in right 
ear, 1.60±0.15 vs 1.69±0.19 in left ear, 1.61±0.21 vs 1.64±0.14 in right ear 
and 1.69±0.12 vs 1.65±0.16 in left ear respectively). 
       The above finding of our study confirms the absence of any peripheral 
hearing impairment in the GTCS group which had been clinically ruled out 
prior to the study by pure tone audiogram. This is consistent with the studies 
of Ehle et al and Fadly et al as they have suggested that GTCS do not seem to 
affect the absolute latency of ABR wave I. However controversy to the above 
finding of our study was shown by Madkow et al in 1998 who had reported 
shortened wave I absolute latency in epileptic patients. 
6.2.2. Wave III 
Absolute  latency  of  wave  III  which  reflects                                            
the time interval measured in millisec from the onset of stimulus to the peak 
of wave III, appear to be significantly prolonged in both right and left ears of  
GTCS patients as compared to controls(3.85±0.23 vs 3.67±0.14 and 
3.95±0.20 vs 3.68±0.22 respectively). When analysing the mean values of 
same latency in both ears of male GTCS patients , it is found to be slightly 
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prolonged especially in the left ear than controls but not statistically 
different(3.83±0.27 vs 3.70±0.23). The finding in the present study is similar 
to the published data of Rodin et al97 who showed that the GTCS patients had 
significantly longer wave III absolute latency than the normal controls. 
Rodin et al97 correlated the ABR wave and interpeak latencies with a 
large variety of clinical variables and showed that statistically significant 
relationships existed mainly in regard to presence or absence brain damage 
and the severity of seizure disorder, as expressed by the number of different 
types of seizures to which a given patient was subject to. They also proved 
that waves II and III showed the most consistent latency prolongations for 
these variables. 
       However controversy to the above finding is suggested by CoS, 
Levinthal et al89 and  Zakaria et al99 who identified that epilepsy do not affect 
the absolute latency of wave III at high intensity. Salem et al90 also refuted the 
above finding of the present study by reporting shortened wave III absolute 
latency and attributed it to the hyperexcitability of the nervous system in 
epilepsy. 
6.2.3. Wave V 
On analysing the present study, it is obvious that the absolute latency 
of ABR wave V which reflects the time interval between stimulus onset and 
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peak of wave V, is found to be significantly prolonged in both right and left 
ears of female GTCS patients when compared to controls (5.67±0.17 vs 
5.47±0.21, 5.71±0.14 vs 5.46±0.26 respectively). The above finding of the 
present study is in accordance with Rodin et al97 who suggested prolonged 
wave V absolute latency in GTCS patients. 
However Usha Panjwani et al83 and  Salem  et  al90 contradicted the 
above findings by demonstrating shortened wave V absolute latency in 
epileptic group as compared to controls. Also the study by Co S,Leventhal et 
al89 elucidates that epilepsy had no significant impact on wave V absolute 
latency. 
6.2.4. IPL I-III 
      On analysing the data of interpeak latencies in the present study, it is 
found that that I-III IPL, an index of the conduction time between cochlea and 
caudal pons is prolonged in both right and left ears of female GTCS 
patients(2.25±0.31vs 2.03±0.19, 2.26±0.23vs 2.03±0.25 respectively). The 
mean values of the same IPL is found to be prolonged in both the ears of male 
GTCS patients but the differences are not statistically significant(2.14±0.35 
vs 1.96±0.26, 2.23±0.39 vs 2.02±0.15 respectively). 
The above finding is consistent with various studies done by Mervaala 
etal,  Chan  et  al  and  Rodin  et  al.  Mervaala  et  al100 demonstrated prolonged 
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I-III IPL and attributed it to the presence of neurological and psychiatric 
defects in their patient population. Chan et al postulated prolonged ABR I-III 
IPL and related such delay to the effect of antiepileptic drugs. Rodin et al97 
observed significantly longer I-III IPL in GTCS patients as compared to 
controls. Auguglia et al88 refuted this finding of the present study by 
demonstrating that  GTCS do not  alter  ABR I-III  IPL. Also S.H.Singh et  al  
reported reduced I-III IPL but the differences were not statistically different. 
6.2.5. IPL I-V 
In the present study, the data analysis makes it clear that ABR I-V IPL 
is significantly prolonged in both right and left ears of female GTCS patients 
as compared to controls (4.07±0.17vs3.83±0.27, 4.02±0.16 vs 3.80±0.33 
respectively). In left ear of male GTCS patients, the same IPL has increased 
but not statistically significant. 
This finding of our study is supported by Rodin et al97 who 
demonstrated significantly prolonged I-V IPL in GTCS patients when 
compared to controls. Also the studies done by Keranen et al, Woo et al and 
Masayuki Ohishi et al125 showed findings similar to the present study 
demonstrating prolonged I-V IPL in GTCS patients. 
94 
 
But  in  contrast  to  the  present  study,  Usha  Panjwani  et  al83 reported 
shortened I-V IPL as compared to controls. Also Aguglia et al88 demonstrated 
normal I-V IPL latency in epilepsy patients. 
6.2.6. IPL III-V 
       On  comparing  the  ABR  III-V  IPL  of  both  male  and  female  GTCS  
patients with controls, it is observed that there exists no significant difference  
between GTCS patients and controls in both ears. This finding makes it 
obvious to conclude that the I-V IPL prolongation is mainly because of the 
increase of I-III IPL with III-V IPL( the conduction time from pons to 
midbrain ) remaining as a constant. Rodin et al97 supports this observation of 
the present study by suggesting epileptic patients with severe brain damage 
have demonstrable brainstem dysfunction affecting mainly the 
medullopontine rather than midbrain or thalamic structures. 
There are no statistically significant differences observed when right 
and left ears of GTCS patients are compared. Fabiano et al also reached 
similar conclusions. No latency difference between the ears are anticipated in 
patients with bilaterally normal auditory thresholds. 
       Engel  J  et  al84 suggests that epileptogenicity is modulated by 
mechanisms which can alter the neuronal excitability and synchronisation 
involving both synaptic and nonsynaptic events. This altered synaptic 
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transmission and/or neuronal conduction lead to reduced wave V absolute 
latency and I-V IPL in GTCS patients. 
Cosi et al85 published in his study that epilepsy patients have their 
BERA values within normal limits. 
       Usha Panjwani et al83 emphasised in their  study that  epilepsy per se 
may produce alterations in BAEPs. These potentials can be utilised in the 
evaluation of AED therapy since the test gives comparatively better 
information about the functional effects of AEDs than blood levels which 
may not appropriately indicate the effective levels at the CNS. 
       Comis  et  al109, Musiek et al110 and Watanabe et al111 observed GABA 
and Ach as the neurotransmitters of auditory system. Loscher et al112 and 
Tower  et  al113 proved that imbalance of these neurotransmitters had been 
correlated with seizure production in epileptic patients. Hence it can be 
speculated that such imbalance of neurotransmitters could extend to a 
subcortical level and be responsible for the dysynchrony of the auditory brain 
stem pathways. 
       Robinson  et  al114 and Selters et al115 proposed the present criteria for 
defining auditory brainstem dysfunction which includes prolongation of IPL 
and /or absence of ABR waves.  
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Yaari Y et al86, Durelli L et al and Eggermont JJ et al87 suggested that a 
slower conduction velocity which is due to the effects on axon membranes, 
synaptic transmission and neuronal integration may prolong the central 
conduction time in GTCS patients. Klutke et al reported prolonged central 
brainstem conduction time in epileptic patients. 
       Gestaut  et  al116,  Kileny et al117,Scherg et al118and Penfield W et al119 
proposed that the thalamocortical pathways and reticular formation are 
involved in the generation of both MLR auditory evoked potentials and 
epileptogenic activity. Sharing some generators of ABR waves, the deep 
epileptogenic foci can directly interfere or inhibit the normal pathway of 
MLR  which  is  the  reason  for  the  diminished  accuracy  of  MLR  relative  to  
ABR in threshold estimation of epileptic patients. 
6.3 Interleukin-1beta levels 
Interleukin -1β is a pro inflammatory cytokine originating peripherally 
or in the CNS, can modulate neuronal excitability and contribute to 
epileptogenesis. If  the influence of IL-1β on epileptogenesis is established, 
this cytokine is an important target to explore possible new antiepileptic 
treatment strategies which are based on interference with intracellular 
signalling cascade that are initiated when IL-1 β binds to its receptor. 
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In the present study, the mean serum level of IL-1 β in GTCS patients 
is 2.15±0.59 pg which is significantly higher when compared to controls 
indicating its potential role in seizure development. This finding of our study 
is consistent with the view of S.Sinha et al91which strengthen the hypothesis 
postulating cerebral production of cytokines triggered by seizures. 
Lehtimaki et al101 and Sinha et al91 observed an increase in serum 
cytokine levels including IL-I β within a few hours after the seizure episode 
followed by a trend towards normalisation by 16 days, thus revealing 
important relationship between seizure and increased cytokine levels. Peltola 
et al92 suggested that increased levels of cytokines including IL-1 β are found 
to be higher after more severe seizure (generalised), suggesting that increased 
levels of cytokines are causally related to the seizure activity. 
       But this finding of the present study is refuted by Rijkers et al93 who 
attempted to determine IL-1 β in plasma of GTCS patients but concluded no 
consistent change was noticed between epilepsy patients and controls. 
Helminen et al96, Matsuo et al123 and Straussberg et al124 proved that blood 
cells of epilepsy patients do not consistently produce more IL-1β in response 
to inflammatory stimulation than blood cells of controls. 
       Bertolani  et  al120, Haspolat et al95 and Virta et al94 observed no 
consistent changes in plasma levels of any of the IL-1 family members in 
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patients with epilepsy. Pacifi et al121 identified that antiepileptic treatment 
does not affect IL-1beta production by mononuclear cells along with 
Hulkkonen et al122 who acknowledged that antiepileptic drugs do not affect 
the plasma levels of IL-1β.  
6.4 Correlation of variables 
There was no significant correlation noted between interleukin-1 beta 
levels and ABR wave absolute latencies and interpeak latencies. Dunn AJ et 
al  and  Fann  MJ  et  al69 reported cytokines including IL-1β influence many 
central neurotransmitters including GABA, 5-hydroxy tryptamine, 
noradrenaline and acetyl choline as well as expression of a number of 
neuropeptides in several brain regions contributing to changes in auditory 
evoked potentials of GTCS patients. 
       The reason for absence of correlation between variables in the present 
study could be attributed to minimum sample size taken in the study and only 
a few percentage of GTCS patients fall beyond the mean±3SD value range of 
normal subjects with respect to all variables assessed in the study. 
         
  
7. CONCLUSION  
  
99 
 
7. CONCLUSION 
The following conclusions have been derived from the present study. 
-  It is proved that GTCS causes prolongation of central conduction time 
since significant variations were found in wave III, V absolute latency 
and I-III, I-V IPL when compared to normal individuals. 
- It is characterised by demonstrable brainstem dysfunction affecting 
mainly the medullopontine rather than thalamic or midbrain structures. 
- Epileptogenicity is the outcome of neurotransmitter imbalance which 
extends to the subcortical level and be responsible for the 
dyssynchrony of the auditory brainstem pathway. 
- The cytokine levels increases significantly in GTCS patients 
suggesting the ccurrence of inflammation in seizures. 
- Since IL-1β activated pathways contribute to epileptogenesis, the 
antagonists can be targeted as novel anticonvulsant drugs. 
- Elevated IL-1β levels   noted in GTCS patients could be the probable 
cause of the observed abnormalities in BERA. 
-  Brainstem evoked response audiometry has emerged as a notable tool 
of  investigation  in studying the central conduction time of epileptic 
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patients and hence may be used to study the functional effects of anti 
epileptic drugs. 
Using BAEP, we can easily detect the early changes occurring in the 
auditory pathway even before the clinical manifestation of hearing deficit 
occurs so that proper measures to intervene the disease at the earliest possible 
is achieved which  brings down the morbidity and provide a better quality of 
life for GTCS patients. So BAEP should be recommended as a routine 
diagnostic procedure in GTCS patients.    
 
 
 
 
 
 
                             
 
 
 
8.SUMMARY 
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8. SUMMARY 
Brainstem evoked response audiometry is a simple, effective and 
noninvasive means of evaluating the functional status of the auditory nerve 
and brainstem auditory sensory pathway. The present study was conducted in 
the Institute of Physiology and Experimental medicine, Madras Medical 
College, Chennai to assess the functional integrity of auditory pathway by 
recording auditory evoked potentials in Generalised tonic clonic seizure 
patients and to elucidate the role of Interleukin-1β in the pathogenesis of 
seizures, in comparison with normal individuals.  
30 GTCS patients and 30 normal subjects participated voluntarily in 
the study and they were subjected to BERA, thereby recording Brain auditory 
evoked potentials. The serum level of interleukin-1β was also measured. 
Statistically significant differences in wave III, V absolute latency and I-III, 
I-V IPL were observed in GTCS patients indicating prolonged central 
conduction time in spite of these patients having normal hearing sensitivity 
assessed by pure-tone audiogram prior to the study. 
The IL-1β levels were significantly higher in GTCS patients when 
compared to controls suggesting the proconvulsant action of this 
inflammatory cytokine and this could be the probable cause of BAEP 
abnormalities noted in these patients. 
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Even though BAEP is in clinical use since 1970s and has got a 
substantial literature to support its efficacy, there is still a paucity of data with 
regard to this investigational tool in patients with seizures. A few published 
data in this field of research also show variable results. From the observations 
of present study, it is clear that GTCS has a significant influence on BAEPs. 
So BAEP may be utilised as a routine objective tool in characterising the 
electrophysiological phenomena of neural excitation, conduction and 
transmission across the auditory pathway.          
       However, the study has got its own limitations as the above findings 
need to be confirmed with a larger sample size. Further research is required to 
reveal the mechanism of nerve injury in GTCS patients and whether this 
occurs in all types of seizures other than GTCS. 
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and serum interleukin 1 beta levels in patients with generalised tonic 
clonic seizures” 
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“Evaluation of Brainstem auditory evoked potential and serum  Interleukin 1 
beta  levels in patients  with generalised tonic clonic seizures” 
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6. I have been advised about the risks associated with my participation in this 
study. 
7. I agree to cooperate with the investigator and I will inform him/her 
immediately if I suffer unusual symptoms.  
8. I have not participated in any research study within the past 
_________month(s).  
9. I am aware of the fact that I can opt out of the study at any time without 
having to give any reason and this will not affect my future treatment in 
this hospital.  
10. I am also aware that the investigator may terminate my participation in 
the study at any time, for any reason, without my consent.  
12. I hereby give permission to the investigators to release the information 
obtained from me as result of participation in this study to the sponsors, 
regulatory authorities, Govt. agencies, and IEC. I understand that they are 
publicly presented. 
13. I have understood that my identity will be kept confidential if my data are 
publicly presented. 
14. I have had my questions answered to my satisfaction. 
15. I have decided to be in the research study. 
I  am  aware  that  if  I  have  any  question  during  this  study,  I  should  
contact the investigator. By signing this consent form I attest that the 
information given in this document has been clearly explained to me and 
understood by me, I will be given a copy of this consent document. 
For adult participants: 
 
Name and signature / thumb impression of the participant (or legal 
representative if participant incompetent) 
 
Name _________________________ Signature_________________  
 
Date________________ 
INFORMATION TO PARTICIPANTS 
Investigator:  Dr.G.Savitha 
 
Name of Participant: 
Title: “Evaluation of Brainstem auditory evoked potential and serum 
interleukin 1 beta levels in patients with generalised tonic clonic 
seizures” 
You are invited to take part in this research/ study /procedures. The 
information in this document is meant to help you decide whether or not to 
take part. Please feel free to ask if you have any queries or concerns. 
You are being asked to participate in this study being conducted in          
          Institute of Physiology and Experimental Medicine, 
          Madras Medical College and Govt. General Hospital, 
          Chennai  -  3  
What is the Purpose of the Research? 
Generalised tonic clonic seizures is a chronic neurological disorder 
characterised by tonic and clonic phases frequently accompanied by the 
presence of hearing deficit. Epilepsy is associated with suppressive effects on 
auditory pathway and hence we want to assess the brainstem auditory evoked 
potential in patients with generalised tonic clonic seizures and correlate the 
serum  interleukin 1 beta  levels with brainstem auditory evoked potential 
in  generalised tonic clonic seizures  so that any hearing deficit if diagnosed 
can be intervened as early as possible. 
The Study Design 
30 patients with generalised tonic clonic seizures will be selected for 
the study. 
Study Procedures 
The study involves assessment of Brainstem auditory evoked potential 
and serum interleukin 1beta levels. 
You will be required to visit the hospital once during the study. 
5ml of blood will be collected simultaneously during the study. Blood 
collection involves prick with a needle and syringe. 
In addition, if you notice any physical or mental changes, you must 
contact the persons listed at the end of the document.  
You may have to come to the hospital (study site) for examination and 
investigations apart from your scheduled visits, if required. 
Possible Risks to you - Nil 
Possible benefits to you- Hearing deficit can be diagnosed at an early stage 
so that proper intervention can be taken. 
Possible benefits to other people 
The result of the research may provide benefits to the society in terms 
of advancement of medical knowledge and/or therapeutic benefits to future 
patients.  
Confidentiality of the information obtained from you 
You have the right to confidentiality regarding the privacy of your 
medical information (personal details, results of physical examinations, 
investigations, and your medical history). By signing this document, you will 
be allowing the research team investigators, other study personnel, sponsors, 
IEC and any person or agency required by law like the Drug Controller 
General of India to view your data, if required. 
The information from this study, if published in scientific journals or 
presented at scientific meetings, will not reveal your identity. 
 
CONCLUSION 
There was significant prolongation of central conduction time in 
GTCS patients even though there was no clinical evidence of hearing 
impairment assessed by pure tone audiogram prior to the study. Hence BAEP 
can be utilized as an objective electrophysiological tool to evaluate the 
functional integrity of auditory pathway from the external ear to lower 
brainstem. 
KEY WORDS 
Generalized tonic clonic seizures, Brainstem auditory evoked 
potential, Absolute latency, Interpeak latency.  
  
How will your decision to not participate in the study affect you? 
Your decisions to not to participate in this research study will not affect 
your medical care or your relationship with investigator or the institution. 
Your doctor will still take care of you and you will not lose any benefits to 
which you are entitled. 
Can you decide to stop participating in the study once you start? 
The participation in this research is purely voluntary and you have the 
right  to  withdraw  from  this  study  at  any  time  during  course  of  the  study  
without giving any reasons. 
However,  it  is  advisable  that  you  talk  to  the  research  team  prior  to  
stopping the treatment 
Name and Signature of impartial witness (required for illiterate patients): 
 
Name _________________________ Signature_________________  
 
Date________________ 
 
Address and contact number of the impartial witness: 
 
Name and Signature of the investigator or his representative obtaining 
consent: 
 
Name _________________________ Signature_________________  
 
Date________________ 
ANNEXURES 
  
PROFORMA 
 
1. Name : 
2. Age: 
3. Sex: 
4. Address : 
5. Occupation : 
6. Complaints/duration: 
7. History of present illness: 
8. History of any hearing problem after the onset of seizures? 
9. Past history: 
10. History of any drug intake 
11. History of associated illness: 
a. Diabetes 
b. Hypertension 
c. Ischemic heart disease 
d. Respiratory diseases 
e. Renal diseases 
Investigations: 
1. Fasting Blood sugar 
2. Serum electrolytes 
3. Pure tone audiometry 
General examination: 
Temperature: 
Pulse rate: 
Blood pressure:  
 
Systemic examination: 
Cardiovascular system: 
Respiratory system: 
Gastrointestinal system: 
Central nervous system: 
ENT examination: 
Brainstem auditory evoked potential study: 
 
Date of conduct of study: 
 
MASTER CHART 
  
SNO AGE SEX BMI IL-1β
Wave I Wave III Wave V IPL I-III IPL I-V IPL III-V Wave I Wave III Wave V IPL I-III IPLI-V IPL III-V     Pg/ml
1 33 M 23 1.7 3.99 5.6 2.29 3.9 1.61 1.31 3.88 5.69 2.57 4.38 1.81 2.22
2 34 M 23.4 1.6 3.41 5.4 1.81 3.8 1.99 1.48 3.93 5.72 2.45 4.24 1.79 2.93
3 32 M 25.5 1.4 3.94 5.58 2.54 4.18 1.64 1.56 4.08 5.86 2.52 4.3 1.78 1.43
4 28 M 25 1.5 3.22 5.7 1.72 4.2 2.48 1.49 3.99 5.81 2.5 4.32 1.82 2.42
5 33 M 27 1.5 3.96 5.67 2.46 4.17 1.71 1.77 3.41 5.49 1.64 3.72 2.08 1.45
6 37 M 23.5 1.6 3.95 5.64 2.35 4.04 1.69 1.69 3.44 5.61 1.75 3.92 2.17 2.11
7 35 M 23.5 1.7 3.61 5.53 1.91 3.83 1.92 1.8 3.32 5.63 1.52 3.83 2.31 1.46
8 29 M 22 1.9 3.71 5.52 1.81 3.62 1.81 1.63 4.15 5.76 2.52 4.13 1.61 2.92
9 29 M 27.5 1.6 4.07 5.78 2.47 4.18 1.71 1.73 4.13 5.8 2.4 4.07 1.67 2.13
10 33 M 22 1.8 3.09 5.01 1.29 3.21 1.92 1.81 3.57 5.26 1.76 3.45 1.69 2.95
11 34 M 25 1.4 3.81 5.59 2.41 4.19 1.78 1.4 3.99 5.71 2.59 4.31 1.72 2.95
12 35 M 24.7 1.6 3.99 5.78 2.39 4.18 1.79 1.48 3.98 5.71 2.5 4.23 1.73 1.91
13 31 M 25.9 1.4 3.71 5.52 2.31 4.12 1.81 1.65 4.02 5.7 2.37 4.05 1.68 1.23
14 29 M 26.9 1.8 3.95 5.76 2.15 3.96 1.81 1.48 4.01 5.66 2.53 4.18 1.65 1.21
15 33 M 24.9 1.7 4.01 5.79 2.31 4.09 1.78 1.77 3.67 5.64 1.9 3.87 1.97 2.91
16 34 F 22.2 1.85 3.77 5.77 1.92 3.92 2 1.77 3.52 5.88 1.75 4.11 2.36 2.04
17 35 F 24.5 1.9 3.52 5.94 1.62 4.04 2.42 1.47 3.88 5.4 2.41 3.93 1.52 2.95
18 29 F 23.3 1.42 4 5.79 2.58 4.37 1.79 1.92 4.08 5.69 2.16 3.77 1.61 2.81
19 28 F 24.3 1.69 3.81 5.59 2.12 3.9 1.78 1.78 4.21 5.84 2.43 4.06 1.63 2.15
20 21 F 25.6 1.73 3.6 5.74 1.87 4.01 2.14 1.62 4.1 5.8 2.48 4.18 1.7 1.3
21 28 F 24.5 1.5 3.64 5.84 2.14 4.34 2.2 1.51 3.92 5.53 2.41 4.02 1.61 2.91
22 35 F 25 1.92 4.03 5.75 2.11 3.83 1.72 1.65 4.02 5.65 2.37 4 1.63 2.78
23 33 F 23.9 1.42 3.52 5.43 2.1 4.01 1.91 1.67 4.08 5.69 2.41 4.02 1.61 1.67
24 33 F 23.4 1.9 4.21 5.84 2.31 3.94 1.63 1.73 3.61 5.83 1.88 4.1 2.22 2.01
25 38 F 22.6 1.56 4.23 5.89 2.67 4.33 1.66 1.88 4.02 5.6 2.14 3.72 1.58 2.07
26 24 F 22.4 1.42 3.71 5.42 2.29 4 1.71 1.61 4.15 5.86 2.54 4.25 1.71 2.34
27 28 F 23.1 1.6 4.05 5.69 2.45 4.09 1.64 1.65 3.71 5.91 2.06 4.26 2.2 2.23
28 25 F 26.6 1.42 3.82 5.43 2.4 4.01 1.61 1.79 3.95 5.57 2.16 3.78 1.62 1.34
29 34 F 22.3 1.33 3.95 5.47 2.62 4.14 1.52 1.77 4.11 5.79 2.34 4.02 1.68 1.41
30 28 F 23.4 1.4 4.02 5.65 2.62 4.25 1.63 1.58 4.01 5.7 2.43 4.12 1.69 2.46
LATENCY IN ms ( RIGHT EAR) LATENCY IN ms ( LEFT EAR)
MASTER CHART FOR GTCS PATIENTS
SNO AGE SEX BMI IL-1β
Wave I Wave III Wave V IPL I-III IPL I-V IPL III-V Wave I Wave III Wave V IPL I-III IPL I-V IPL III-V    Pg/ml
1 35      M 23.1 1.77 3.94 5.7 2.2 3.92 1.75 1.42 3.4 5.6 1.9 4.18 2.2 1.35
2 29      M 24.2 1.54 3.79 6 2 3.92 1.79 1.65 3.7 6.1 2.05 4.5 2.4 2.7
3 37      M 25.3 1.65 3.73 5.6 2.1 3.92 1.83 1.73 3.5 5.4 1.8 3.6 1.9 1.35
4 36      M 26.6 1.63 3.29 5.4 1.66 3.77 2.11 1.67 3.3 5.6 2.03 3.93 2.3 2.5
5 39      M 23.3 1.69 3.69 5.5 2 3.81 1.81 1.42 3.9 5.4 2.5 3.9 1.46 1.31
6 38      M 26 1.92 3.9 6 2 4.1 2.13 1.77 3.9 5.7 2.13 3.93 1.8 1.21
7 24      M 24.1 1.65 3.85 5.8 2.2 4.17 1.96 1.42 3.5 5.4 2.08 3.98 1.9 1.31
8 32      M 23.5 1.9 3.69 5.6 1.8 3.67 1.88 1.56 3.6 5.7 2.04 4.14 2.1 1.55
9 31      M 24.9 1.42 3.69 5.4 1.8 3.98 1.71 1.69 3.7 5.4 2.01 3.71 1.7 1.89
10 36      M 24.5 1.98 3.81 5.6 1.83 3.62 1.79 1.65 3.6 6.15 1.95 4.5 2.55 1.92
11 26      M 22.9 1.77 3.73 5.8 2 4 2.04 1.77 3.7 5.6 1.93 3.83 1.9 2.9
12 28      M 24.5 1.31 3.98 5.7 2.7 4.42 1.75 1.9 3.9 5.3 2 3.4 1.4 1.9
13 34      M 24.7 1.98 3.75 5.5 1.77 3.52 1.75 1.81 3.9 5.3 2.09 3.5 1.4 1.72
14 36      M 24.5 1.52 3.44 5.4 1.92 3.88 1.96 2.17 4.2 5.73 2.03 3.56 1.53 1.61
15 29      M 26 1.85 3.51 5.6 1.66 3.75 2.09 1.77 3.7 5.6 1.9 3.83 1.9 2.11
16 33      F 23.4 1.42 3.44 5.8 2.02 4.38 2.36 1.65 3.7 5.52 2.1 3.87 1.82 1.1
17 31      F 22.9 1.69 3.9 5.6 2.2 3.91 1.7 1.77 3.5 5.6 1.7 3.83 2.1 1.91
18 28      F 24.5 1.77 3.56 5.3 1.8 3.53 1.74 1.94 3.7 5.21 1.8 3.27 1.51 1.87
19 21      F 25.4 1.73 3.48 5.2 1.75 3.47 1.72 1.6 3.6 5.31 2 3.71 1.71 1.78
20 22      F 24.2 1.6 3.73 5.6 2.1 4 1.87 1.77 3.4 5.35 1.6 3.58 1.95 2.31
21 24      F 25.1 1.73 3.6 5.4 1.9 3.67 1.8 1.44 3.7 6.15 2.3 4.71 2.45 1.56
22 27      F 24.1 1.63 3.94 5.2 2.3 3.57 1.26 1.56 3.4 5.23 1.8 3.67 1.83 2.8
23 33      F 23.4 1.85 3.73 5.7 1.9 3.85 1.97 1.73 4.2 5.65 2.5 3.92 1.45 1.56
24 32      F 23.7 1.65 3.6 5.4 2 3.75 1.8 1.33 3.4 5.19 2.1 3.86 1.79 1.21
25 37      F 23.9 1.63 3.77 5.4 2.1 3.77 1.63 1.54 3.9 5.4 2.4 3.86 1.5 1.87
26 35      F 25.5 1.48 3.67 5.1 2.2 3.62 1.43 1.6 3.7 5.6 2.1 4 1.9 1.76
27 34      F 23.1 1.77 3.73 5.7 2 3.93 1.97 1.94 3.9 5.25 1.9 3.31 1.35 1.61
28 26      F 24.1 1.42 3.6 5.6 2.2 4.18 2 1.67 3.6 5.69 1.9 4.02 2.09 2.87
29 29      F 23.1 1.48 3.77 5.7 2.3 4.22 1.93 1.56 3.7 5.19 2.1 3.63 1.49 1.72
30 24      F 23.4 1.81 3.5 5.4 1.7 3.59 1.9 1.73 3.9 5.6 2.2 3.87 1.7 1.13
LATENCY IN ms ( RIGHT EAR ) LATENCY IN ms ( LEFT EAR )
MASTER CHART FOR CONTROLS
KEY TO MASTER  CHART 
BMI   - Body Mass Index 
IPL   - Interpeak Latency 
IL-1β  - Interleukin – 1 Beta 
ms   - Milliseconds 
  
